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SUMMARY 
Background 
Asthma is one of the most common chronic diseases among children, adolescents and young 
adults. The use of drugs to treat asthma has not been widely investigated in the Norwegian 
population and there has been a lack of longitudinal data. Most studies have been conducted 
in confined age groups and geographic regions. The occurrence of additional health problems 
in the young population with asthma has important implications for the management of 
asthma and needs investigation. Asthma is a clinical diagnosis that is not easily captured in 
population-based studies and there is no agreement on a gold standard for measuring asthma 
in epidemiology. Prescription data on asthma drug use may be a useful proxy measure for 
identifying individuals with current asthma in the population. 
Objectives 
The main objectives of this thesis were to study issues related to asthma in the Norwegian 
population of children, adolescents and young adults. Three areas have been studied: Asthma 
drug use, asthma drug use as a proxy measure of asthma, and selected additional diseases and 
drug treatments occurring in individuals with asthma. 
Materials and methods 
This thesis rests on data from population-based databases and questionnaires: 1) The 
Norwegian Prescription Database, 2) The Norwegian Mother and Child cohort study 
questionnaire for seven years old participants, 3) The Youth Health Surveys in five counties, 
4) The Population and Housing Census from 2001, and 5) The Central Population Register. 
Data on filled prescriptions from the Norwegian Prescription Database is the central source 
for information and provided the outcome variables in all papers of this thesis.  
Main findings 
Mother-reported use of asthma drugs in children had high validity, compared to prescription 
data of asthma drug use. Furthermore, the prescription data on asthma drugs corresponded 
well with maternal reports of current physician-diagnosed asthma, and few individuals with 
no reported asthma had filled prescriptions. Filled prescriptions were used as a proxy measure 
in the other papers in this thesis to identify individuals with current asthma in the study 
populations.  
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The prevalence and incidence of asthma drug use in the Norwegian population 2-29 years old 
was highest in preschool children and lowest in young adults. Males had higher levels than 
females at a young age, but this changed from about 15 years of age to higher levels in 
females. The persistence to asthma drugs over time was relatively low, with less than half of 
asthma drug users receiving drugs in three consecutive years. The type of asthma drugs used 
varied substantially by age but not by gender, and there were indications of suboptimal 
pharmacotherapy.  
The occurrence of chronic diseases in individuals with asthma was assessed by utilizing 
diagnostic codes provided by physician on reimbursed prescriptions. Several diseases 
occurred more frequently in children, adolescents and young adults with asthma than in the 
Norwegian general population. A majority of the asthma population had one of the nine 
comorbid diseases examined, while few had more than one of the comorbidities. In another 
study, young adults with asthma were at an increased risk for initiating use of hypnotic drugs. 
The risk was highest among individuals who recently had received asthma drugs, indicating 
that they had currently active asthma disease. 
Conclusions 
The findings in this thesis indicate that prescription data may serve as a proxy for current 
asthma in the population. It is important to carefully consider the length of the capture period 
for prescription data and possible overlapping conditions treated with the same drugs in 
different age groups. The relatively low persistence to asthma drug use may reflect the 
variability of asthma within and between patients, and illustrate the challenges encountered in 
defining asthma in epidemiologic studies. Several diseases and drug treatments occurred more 
frequently in the asthma population. The presence of comorbidities may influence and 
complicate several aspects of asthma and both the causes and consequences of comorbidities 
need further investigation.  
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1 BACKGROUND 
1.1 General introduction 
Epidemiology is defined in several ways but a common definition is the study of the 
distribution and determinants of disease or illnesses in populations. Alternatively, it can be 
defined as the study of the distribution of health-related states and events in populations, thus 
also encompassing positive outcomes and physiologic states as well as diseases and illnesses 
(1). Pharmacoepidemiology is a branch under epidemiology and has been defined as “the 
study of the use of and the effects of drugs in large numbers of people” (2). It applies the 
methods of epidemiology on the content area of clinical pharmacology (the effect of drugs in 
humans) and aims to describe, explain and predict use and effects of drugs in a defined time, 
space and population. The major application area for pharmacoepidemiological principles is 
in post-marketing studies of drugs, where its main asset compared to the pre-marketing 
randomized controlled trials (RCTs) is the study size and “real life” setting. It may provide 
new information about rare adverse events or supplement information from RCTs about 
patients groups that have not been studied in RCTs such as children and pregnant women.  
 
The increased availability of computerized databases containing medical care data, e.g. 
prescription data, has facilitated analyses of patient-level drug effects on a population-based 
scale. Such databases have been available and used for pharmacoepidemiological research in 
North America since the 1980s and included claims data used for reimbursement of health 
care costs (2). Databases have also been available in Europe, where some databases were 
developed specifically for research purposes. From January 2004, a research database 
containing prescription data covering the entire Norwegian population has been available, the 
Norwegian Prescription Database (NorPD) (3, 4). Before 2004, information about drug use in 
the entire Norwegian population was only available as sales statistics from pharmacies and 
wholesalers, i.e. not on an individual level. Therefore, NorPD gives opportunities to study 
patterns, determinants and consequences of drug use in the population. Furthermore, by using 
the unique person identity number assigned to all individuals living in Norway, information 
relevant to the study of drug use may be linked from other health registers, population surveys 
and biobanks (4).  
 
 2  
This thesis focuses on aspects of the epidemiology of asthma drug use, and data from NorPD 
is the central source of information throughout. The field of pharmacoepidemiology is quite a 
new research field in Norway and very few population-based observational studies on the use 
of asthma drugs have been conducted. Inferences about the epidemiology of asthma disease 
may also be made from studies of asthma drug use, because the asthma drug treatment is 
intimately linked to asthma. Particularly in school-aged children, adolescents and young 
adults, there are few overlapping diseases that are treated with asthma drugs. There is some 
diagnostic and therapeutic overlap with Chronic obstructive pulmonary disease (COPD) in 
older adults and the studies in this thesis were confined to the population under 30 years of 
age. Diagnosis of asthma in preschool children is difficult due to unspecific symptoms but 
this group of children was also studied. There are some advantages of using NorPD data when 
studying a disease as varied in time, space and within patients as asthma; the data is routinely 
collected and updated regularly, and covers all age groups and geographical regions 
continuously. However, issues concerning definition and classification of asthma encountered 
in epidemiologic asthma research are still present, and these issues are discussed briefly in the 
following chapters. 
1.2 Asthma 
1.2.1 Definition, diagnosis and etiology 
Asthma is a chronic, inflammatory disease of the airways characterized by recurrent 
reversible airflow obstruction. The pathogenesis involves several cells and mediators but has 
not been fully understood, and the definition of asthma is based on the functional 
consequences of asthma. The airway inflammation is associated with bronchial 
hyperresponsiveness to a variety of stimuli and causes symptoms such as recurring episodes 
of wheezing, breathlessness, chest tightness and cough (5). Asthma is a heterogeneous 
condition and there is great variability within and between individuals in terms of clinical 
expression, age at onset, and persistence of symptoms over time (6-9). Although it is regarded 
as a chronic disease, remission and later relapse of asthma during shorter or longer periods is 
a common feature. The persistence of asthma over time is correlated with the age of onset and 
there may be several phenotypes of asthma that have different risk factors, severity and long-
term outcomes (7, 8, 10). There is increasing awareness of the heterogeneity of asthma but 
distinct subgroups based on objective criteria have not been identified yet (8, 11). 
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Asthma is a clinical diagnosis with no single characteristic or test that alone can identify 
asthma. The diagnosis is based on several components, such as symptom history, clinical 
examination, lung function tests, airway challenge tests, measurement of allergic status and 
exclusion of differential diagnoses.  The clinical symptoms are variable and non-specific 
which complicates the diagnosis, particularly in preschoolers where asthma diagnosis is 
primarily one of exclusion of differential diagnoses (5, 12). Episodes of wheeze is common 
also in non-asthmatics at this age, e.g. during viral infections, while airflow limitation and 
inflammation is not easily assessed (12, 13). Middle-aged populations also have differential 
diagnoses, with COPD becoming a prominent cause of respiratory disease during the fifth 
decade of life (12). 
 
The etiology of asthma is not fully understood and there is a multitude of suggested risk 
factors and triggers for asthma, some of which are both. These factors may be classified as 
host factors and environmental factors. Host factors include genetics, as well as obesity, 
gender and age. Environmental factors include allergens such as fungal spores and house dust 
mite, irritants, tobacco smoke and respiratory infections in early life. The “hygiene 
hypothesis” (14) and variants of this hypothesis suggested that exposure to certain allergens 
and infections in early life influence the development of the immune system and leads to 
reduced risk of allergic diseases including asthma. However, evidence supporting this 
hypothesis is inconclusive and other exposures in utero or early infancy have received 
increasing focus (15, 16).  
1.2.2 Measuring asthma in epidemiological studies 
An apparent increase in the occurrence of asthma has been reported during several decades in 
westernized countries while recent reports suggest that this increase has levelled off (17-20). 
It has been questioned whether the increase is due to a genuine increase in people suffering 
from asthma or if it is due to changes in how asthma is measured and perceived (10, 17, 19, 
21, 22). Physicians may have changed their criteria for using the label asthma when patients 
present with respiratory symptoms, especially mild and transient cases (10, 17, 19, 21-25). 
Furthermore, an increased awareness in the general public and better access to care may have 
lead to increased perception of respiratory diseases. Regarding comparisons across countries, 
translation and interpretation of questionnaires on asthma symptoms can be challenging. For 
instance, the English word “wheeze” is often used in questionnaires but translation is difficult 
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(26). It has been observed in inter-country questionnaire studies that English-speaking 
countries report relatively high prevalence of asthma symptoms such as wheeze (27).  
 
An inherent problem of asthma is that there is no single diagnostic test or criterion both 
necessary and sufficient to diagnose asthma. The diagnosis is based on factors not easily 
captured in epidemiological studies (e.g. patient history, clinical examination, exclusion of 
differential diagnosis), and it is therefore challenging to determine the occurrence of asthma 
in the population. There is currently no agreed upon gold standard for measuring asthma in 
epidemiological studies (28), and a multitude of definitions of asthma that are different in 
several domains have been used.  
 
The source of the data in epidemiological studies of asthma may come from birth cohorts, 
census surveys in the general population, or registers such as hospital discharge databases, 
administrative data from physicians and prescription databases. These data sources have 
different types of data such as questionnaires, telephone or face-to-face interviews, or 
electronic records from databases. There are also differences in who reports, e.g. self-reports, 
parent-reports or physician reports. The disease entity that is measured is highly variable and 
includes asthma per se (no further specification), specific symptoms of asthma, confirmed 
doctor diagnosis, drug use for asthma, or physiologic measures (e.g. spirometry or bronchial 
hyperresponsiveness). However, physiologic measures are rarely available in large population 
studies. Furthermore, the time frame of the measure is important to consider in a time-varying 
disease such as asthma. The terms “ever” and “current” asthma are commonly used, the latter 
often operationalized as asthma during last 12 months.  
 
Different combinations of these domains of asthma measures are used and has lead to a 
multitude of asthma definitions: One recent study reviewed the literature and found 60 
different operational definitions in 122 papers on childhood asthma (29). The prevalence 
varied from 15% to 51% when some of the definitions were applied to an ongoing cohort 
study of 6-year old children (the children included were “at risk” of developing asthma, 
possibly explaining the high prevalence figures). Thus, the choice of outcome measure has 
high impact on the estimated occurrence of asthma and different measures do not identify the 
same set of individuals.  
 
 5  
These issues may contribute to the substantial variability of reported occurrence of asthma in 
different studies and between countries. A possibly more pressing concern than determining 
the exact prevalence level in the population is to identify factors that cause asthma. Asthma is 
heterogeneous over time in the same individual, with remission and relapse of the clinical 
symptoms over shorter and longer periods (6, 30, 31). This makes it challenging to study risk 
factors, as the same individual may switch from being regarded as asthmatic to non-asthmatic 
depending on when the information is collected (28). Moreover, this variability may stem 
from both changes in exposure to triggers (e.g. seasonal allergy) and from factors inherent in 
the disease.  
 
Self-reported asthma symptoms and/or doctor-diagnosed asthma are often used in population 
studies of asthma. However, this way of separating asthmatics from non-asthmatics is queried 
because of subjective symptom recognition and recall bias (21, 23, 24, 32). Questionnaire 
studies may also have problems with capturing seasonal variations in asthma, depending on 
the point in time questionnaires were filled in and the recall period used. Moreover, the 
generalizability of such studies to the general population may be compromised if the study is 
conducted only in a local population or narrow age groups.  
 
An alternative method to identify asthmatics in the general population is to utilize data from 
administrative databases that routinely collect information on the use of health care services. 
One such data source is prescription registers. The drugs used for asthma are quite specifically 
used for asthma and the use of drugs to control asthma is a key component in asthma 
management (5). Thus, drug use could serve as a proxy measure of current asthma. 
International studies have shown the feasibility of drug prescriptions to identify individuals 
with asthma (33-36). Administrative registers like prescription databases have some 
advantages in that they include routinely collected data covering continuous time periods and 
are not collected on an ad hoc basis. The mandatory and automated capture of drug exposure 
and other variables diminishes selective reporting and participation, and facilitates the 
assessment of time sequence of events. Furthermore, these databases often have larger 
population size than studies dependent on the distribution of a large number of questionnaires. 
Among the limitations of administrative databases are that data are generated by a complex 
health care system and it may not always be transparent how the data come about. 
Furthermore, the collected information is not tailored to the research question. 
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1.2.3 Occurrence of asthma in the population 
As delineated in the previous chapter, determining the occurrence of asthma in the population 
from published literature is difficult because of considerable variation in the applied 
definitions of asthma and representativeness of study populations. However, it is generally 
accepted that asthma is the most common chronic disease among children, and it is also 
common in the adolescent and adult population (37, 38). It has been estimated to affect as 
many as 300 million people globally (5). 
 
Two major multi-center collaboration studies regarding asthma have been conducted in 
different countries: 1) The International Study of Asthma and Allergy in Children (ISAAC) 
among children and adolescents, and 2) the European Community Respiratory Health Survey 
(ECRHS) among adults. These studies use standardized questionnaires across countries and at 
several time points, and have reported large differences between countries in the asthma 
prevalence level and time trends (38-40). For instance, an ISAAC study reported prevalence 
of ever asthma ranging from about 2% to over 30%, with similar variations in reported current 
wheeze (40). The prevalence of asthma has been reported to be increasing globally during the 
last four decades of the 20th century (18). Some recent studies have reported a further increase 
while a leveling off or even a decrease in prevalence among children and young adults has 
been reported in some westernized countries (17, 18, 20, 40-42). This has also been observed 
in a repeat survey in Norway among 9-11 year olds, especially in girls (43).  
 
There is a relatively large variability between Norwegian population-based studies in the 
reported prevalence of asthma between age groups, but also in the same age groups. In 4-5 
year olds, the prevalence of current asthma has been reported to be 6.5% (44), while a 
cumulative prevalence of 8.7% and current prevalence of 7.7% has been reported (45). 
Among 10-year olds, a lifetime prevalence of 20% is reported (46), while current asthma has 
been reported in respectively 11% (46) and in 5.6% (47). Among adolescents, current asthma 
has been reported to be between 7 and 10 % (48) while in adults (15-70 years) a prevalence of 
ever doctor-diagnosed asthma has been reported in 7.6% of males and 10.7% of females (49). 
These studies were conducted during different time periods, and they were restricted to 
specific geographical areas and age groups, and they measured different disease entities and 
phrasings of questions, thus complicating comparisons.  
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1.2.4 Comorbidities of asthma  
Comorbidity may be defined as the occurrence of one or more additional diseases in 
individuals who have an index disease (50). Asthma is a common disease in the young 
population and may co-occur (i.e. comorbid) with several diseases and illnesses. The extent 
and impact of comorbidities in asthmatics has received little attention compared to other 
chronic diseases like cardiovascular diseases and diabetes. This could in part be due to 
multimorbidity increasing with age while asthma is most prevalent in young populations (51). 
It is important to study comorbidities of asthma in the exploration of possible common causes 
or pathways for development of asthma and other diseases. Furthermore, the consequences of 
having comorbid diseases and its implications for asthma management are important to 
characterize. Comorbidities influence several aspects of asthma, such as detection and 
diagnosis, severity and changes in severity over time, and control of asthma symptoms (52-
54). Additionally, the response to asthma therapy may be different and adherence to asthma 
therapy may decrease (55, 56). The use of health services is reported to be higher in 
asthmatics with comorbidities, and places an extra burden on the healthcare system and costs 
(57, 58). Identification and treatment of comorbidities is part of the core management of 
asthma, especially for more severe cases (5).  
 
Associations between asthma and several conditions have been reported and some of the 
widely studied conditions are included in management guidelines for asthma. These include 
allergies, gastro-oesophageal reflux disease (GORD), and bacterial and viral respiratory tract 
infections (5, 59-61). The presence of allergy is even part of the definition of some proposed 
asthma phenotypes (61, 62). Other conditions linked to asthma include depression, anxiety 
and sleep problems (63, 64). 
1.3 Treatment of asthma 
1.3.1 Guidelines for management of asthma 
Several national and international guidelines and expert reports have been compiled to guide 
physicians in the assessment and management of asthma (5, 65-68). Broadly speaking, 
guidelines adopt the same approach to asthma management (69). One of the most cited 
guidelines is the one issued by the Global Initiative for Asthma (GINA), which was launched 
in 1993 in collaboration with the National Heart, Lung, and Blood Institute in the USA and 
the World Health Organization. The first report was issued in 1995 and was last updated in 
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2009 (5). Specific guidance for the management of asthma in preschool children has been 
published, due to issues concerning diagnosis and pharmacotherapy at this age (13, 68, 70). 
 
Management of asthma includes several components such as monitoring of the disease, 
education of patients, control of environmental factors and pharmacotherapy. The medical 
treatment should follow a stepped care approach and the goal is to achieve and maintain 
control of asthma symptoms (5). Thus, step-up and down in therapy intensity by increasing 
doses and/or adding or changing type of asthma drugs is guided by the clinical control of 
asthma, while also taking into account the risk of adverse effects. The limited understanding 
of the etiology of asthma and identification of specific subgroups of asthma precludes the 
development of effective prevention strategies, and there is no affirmative evidence for 
interventions that modify the long-term course of asthma (5, 9, 16, 71-73). 
1.3.2 Asthma drugs 
The asthma drugs can broadly be classified as long-term controllers and quick-relief drugs but 
these categories are not mutually exclusive. The controllers have mainly anti-inflammatory 
effects while the relievers act mainly through bronchodilating effects (5, 74). Corticosteroids, 
with their multiplicity of anti-inflammatory properties, are the most effective controller drugs 
for the treatment of persistent asthma and have well-documented effect on clinical outcomes. 
Administration of glucocorticoids through inhalers is preferred over systemic administration 
as it gives higher local concentration of the drugs in the lung and lower risk of systemic side 
effects. Systemic administration is recommended for severe uncontrolled asthma and during 
acute exacerbations. Other controllers available in Norway are leukotriene receptor 
antagonists, long-acting 2-agonists (LABA), cromones, xanthine derivatives (theophylline) 
and anti-IgE therapy (omalizumab) (75). These drugs are mainly used as add-on therapy if 
patients fail to achieve asthma control with inhaled corticosteroids, although leukotriene 
receptor antagonists may be used as the only controller drug (5, 75). LABA should be used 
only in combination with other controllers (e.g. corticosteroids) due to risk of serious adverse 
events during monotherapy (5, 75, 76). LABA is available as fixed-dose combination inhalers 
with corticosteroids as well as single component inhalers. 
 
Relievers should be used as needed to relieve bronchoconstriction and all patients should have 
these available. They are generally not recommended as monotherapy except for individuals 
with mild, intermittent asthma (5, 67, 75). The most widely used relievers are inhaled short-
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acting 2-agonists (SABA). Other reliever drugs include anticholinergics and oral short-acting 
2-agonists.  
1.3.3 Reimbursement scheme for drugs 
All drugs used for asthma are covered by the national tax-supported public health service 
which all Norwegian citizens have unrestricted access to (77). Reimbursement should be 
granted only if the patient has a chronic condition where long term drug treatment is needed. 
“Long term” is operationalized as needing more than 3 months of regular or intermittent 
treatment during one year. Patients pay 38% of drug costs but no more than 520 NOK per 3 
months treatment (2010). Furthermore, there is a ceiling for patient co-payment per year for 
reimbursed drugs, physician visits, outpatient visits and some other healthcare expenses (1840 
NOK in 2010). There is no co-payment for children less than 16 years of age (12 years of age 
before 2010 and 7 years of age before 2006).  
 
The system for general reimbursement of drugs is a “positive list” system, based on a list of 
diseases or conditions for which specified drugs can be reimbursed. The Norwegian Medical 
Products Agency maintains the list of drugs and corresponding diagnosis that is eligible for 
general reimbursement (78). If a drug or diagnosis has not been granted general 
reimbursement, physicians may apply on behalf of the patient for individual reimbursement of 
the drug treatment.  
 
Physicians write a specific reimbursement code on prescriptions deemed eligible for general 
reimbursement. Earlier, the reimbursement codes were numbers that corresponded to specific 
diseases or disease groups, and asthma and COPD had the same number code. From July 
2006, asthma and COPD were differentiated in the reimbursement system by assigning them 
different number codes. From March 2008, all number codes were substituted with codes 
from two diagnostic coding systems: The International Classification of Diseases version 10 
(ICD-10) and the International Classification of Primary Care version 2 (ICPC-2). After a 
one-year transition period, all filled prescriptions with reimbursement were required to have 
diagnostic codes from 3 March 2009. 
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1.3.4 Occurrence of asthma drug use in the population 
There are few Norwegian studies of the extent of asthma drug use in the general population. 
One study conducted in four Norwegian counties among 15-16 year olds during 2000-2002 
found the self-reported asthma drug use during the previous four weeks to be 5.8% in males 
7.0% in females (79). An ECRHS study in 14 countries among 20-48 year olds studied the 
prevalence of self-reported asthma drug use during the previous 12 months (80). In the 
Norwegian sample, the prevalence was 3.6% in the first survey (1990-1994) and 7.7% in the 
second survey (1998-2003). A prescription database study of the entire Norwegian population 
under 19 years of age estimated the one-year prevalence of different categories of asthma 
drug use during 2004 (81). 9.1% of the population used any drug for obstructive airways 
disease (Anatomical Therapeutic Chemical (ATC) code R03), while 5.4% of the population 
used inhaled asthma drugs (R03AC, R03AK, R03BA) that were reimbursed for use in asthma. 
The prevalence was 4.6% in girls and 6.2% in boys and the gender difference varied by age; a 
higher prevalence was observed in males during childhood, and shifted to a higher prevalence 
in females during adolescence.  
 
The prevalence of asthma drug use in young adults has not been widely investigated in 
population-based studies. One Danish prescription study conducted in 1990-91 found a one-
year prevalence of asthma drug use in 20-44 year olds to be 3.6% (82). The aforementioned 
ECRHS study in 20-48 year olds reported overall prevalence in all 14 countries of 6.8% 
(1990-1994) and 9.5% (1998-2003) (80). In children and adolescents, studies have been 
conducted in several European countries and the reported prevalence was highly variable and 
ranged from 4% to 26% (36, 83-85). However, some studies included all drugs used for 
obstructive airways disease (ATC code R03). Some of these drug classes may be used for 
other indications that asthma, such as unspecific respiratory tract symptoms and infections, 
especially in preschool children. Thus, there may be significant heterogeneity in the 
populations included in these studies.  
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2 AIMS OF THE STUDIES 
The main objectives of this thesis were to study issues related to asthma in the Norwegian 
population of children, adolescents and young adults. Three areas were studied: 
• Asthma drug use. 
• Asthma drug use as a proxy measure for asthma. 
• Additional diseases and drug treatments occurring in individuals with asthma.  
 
The specific research questions to answer were: 
1. Examine the validity of maternal reports of asthma drug use (paper I). 
2. Examine the validity of dispensed asthma drugs as a proxy measure of asthma (paper I). 
3. Study the gender- and age-specific annual prevalence and incidence and the persistence to 
asthma drug use (paper II). 
4. Explore the type of asthma drugs used (paper II). 
5. Examine whether young adults with asthma are at higher risk of initiating use of hypnotics 
(paper III). 
6. Examine whether specific chronic conditions and antimicrobial treatment occur more 
frequently in asthmatics than in the general population (paper IV). 
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3 MATERIALS AND METHODS 
3.1 Sources of data 
The papers in this thesis are based on data from two population registers, one health survey 
one birth cohort study, and one population census: The Norwegian Prescription Database 
(NorPD) (paper I-IV); Data from a pilot questionnaire distributed to mothers of 7-year old 
children in the Norwegian Mother and Child (MoBa) cohort study (paper I); The Youth 
Health Surveys (YHS) from five Norwegian counties (paper III); The Population and Housing 
Census (PHC) conducted in 2001 (paper IV); The Central Population Register (CPR) (paper 
II, III and IV). 
 
Data from NorPD served as the outcome variable in all papers and were linked at the 
individual level to the other data sources (paper I-IV). Data linkage was conducted by using 
the unique, encrypted 11-digit person identity number (PIN), assigned to all individuals 
residing in Norway (3, 86).  
3.1.1 Norwegian Prescription Database (NorPD) 
From 1st January 2004, it was mandatory for all Norwegian pharmacies to send electronic data 
on all dispensed drugs to the NorPD (in Norwegian: Reseptregisteret). NorPD is run and 
owned by the Institute of Public Health (3, 4, 87). Included in the database are dispensed 
drugs with and without reimbursement from prescribers of any occupation and specialty. I.e. 
NorPD includes drugs prescribed by specialists in secondary or tertiary care for use in the 
ambulatory care setting. Thus, NorPD covers dispensed drugs for the entire non-
institutionalized population and data are stored on an individual patient level. Drugs delivered 
to nursing homes and to physicians for use in their own practice are included in NorPD as 
well, but these data are not on the patient level. 
 
NorPD stores information about the patient (encrypted PIN, gender, age), the prescriber of 
the drug (encrypted prescriber identity number, specialty), the pharmacy dispensing the drug 
(pharmacy identifier, location) and information about the dispensed drug (date of dispensing, 
name and ATC code of drug, reimbursement status) (this is not an exhaustive variable list). 
All drugs in Norway are classified according to the Anatomical Therapeutic Chemical 
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classification system (ATC code) and these codes are used for identification of drugs and drug 
classes (88).  
 
NorPD data were used in all papers (I-IV) of this thesis. 
3.1.2 Norwegian Mother and Child Cohort Study (MoBa) 
The MoBa cohort study (in Norwegian: Den norske mor og barn-undersøkelsen) is a 
prospective population-based pregnancy cohort study conducted by the Norwegian Institute of 
Public Health and enrolled over 100,000 pregnancies during 1999-2008 (89, 90). Pregnant 
women from all over Norway were invited by mail to participate in connection with the 
routine ultrasound examination offered to all pregnant women at 17-18 weeks of gestation. A 
total of 38.5% of the women invited during 1999-2008 gave consent to participate (91). 
Mothers received three questionnaires during pregnancy while fathers received one. After 
birth, both mothers and fathers receive several questionnaires at specified ages of the child. 
Additional information about the MoBa study and questionnaires are available on the website 
of the Institute of Public Health (90). During March-June 2008 mothers of 3,394 children in 
MoBa who had reached 7 years of age received a pilot questionnaire, which included several 
questions regarding asthma and allergy (see questionnaire in appendix I).  
 
The study in paper I rested on the pilot questionnaire. 
3.1.3 Youth Health Surveys (YHS) 
The population-based YHS (in Norwegian: Ungdomsundersøkelsene) were conducted during 
2000-2005  in 6 of 19 Norwegian counties: Oslo 2000-2001; Hedmark 2001; Oppland 2002; 
Finnmark 2003; Nordland 2004; Troms 2002-2003 and 2005 (only in the main city Tromsø) 
(92). The YHS included questions on health, lifestyle, socioeconomic factors and living 
conditions (see questionnaire in appendix II). 10 years of school is compulsory in Norway and 
most students are 15-16 years of age at the time. All 10th grade students in each respective 
county were invited to fill in a self-administered questionnaire during two lessons in the 
spring term. A project assistant was present in each classroom to clear up possible 
misunderstandings and questionnaires were left at school to be completed by students not 
present. In Oslo, Oppland and Hedmark, questionnaires were sent to the home of those that 
did not respond during the course of the school year. In Troms and Finnmark, respectively 
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9.5% and 23% of the schools did not participate in the school-based survey and students 
received a postal questionnaire and one reminder instead. Both the mail survey and the 
school-based survey from these counties had lower participation rate than in the other 
counties (Troms 2002-2003; 81.7%, Finnmark 2003; 71.1%). The mean response rate in all 
six counties was 86.5%.   
 
Paper III was based on the surveys conducted in five counties during 2000-2003 (15,436 
individuals invited, 86% response rate). 
3.1.4 Population and Housing Census (PHC) 
The PHC (in Norwegian: Folke- og boligtellingen) consists of data from several 
administrative registers as well as data from a questionnaire sent to every family in Norway 
(93). The census has been conducted about every 10 years and it is mandatory to participate 
for all residents. The last census was conducted in 2001 and included all persons, also foreign 
citizens, considered resident in Norway on 3 November 2001 according to the Central 
Population Register (CPR).  
 
Paper IV was based on the census conducted in 2001. Only variables from registers were 
utilized (encrypted PIN, date of birth and gender).  
3.1.5 Central Population Register (CPR) 
The CPR (in Norwegian: Folkeregisteret) is owned by the Norwegian Tax Administration 
while Statistics Norway maintain the register for research purposes. It includes continuously 
updated information about every person residing in Norway (94, 95). Information from the 
CPR used in the present thesis was the encrypted PIN and the date of death and emigration.  
 
Aggregated data from CPR by gender and age groups on the number of people residing in 
Norway was retrieved from the website of Statistics Norway (paper II) (96). Individual level 
data files from CPR were used to determine if persons were alive (paper II-IV) and still 
residing in Norway (paper III and IV).  
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3.2 Definition of asthma drug use and asthma 
The use of asthma drugs in the Norwegian population was examined in the present thesis by 
analyzing data on filled prescriptions from NorPD. In paper I, the congruence between asthma 
drug use as registered in NorPD and maternal reports of asthma drug use was examined. In 
paper II, the use of asthma drugs in the entire Norwegian population was examined by using 
NorPD data. As delineated in chapter 1.2.2, the use of asthma drugs is a core component in 
the management of asthma and may serve as a proxy measure of current, active asthma 
needing drug treatment. In paper I, the congruence of this proxy measure and maternally 
reported asthma was examined. In paper II-IV, the proxy measure was utilized to identify 
individuals with current asthma from the study populations. 
 
The asthma drug classes to include in a proxy measure of asthma has been explored in a 
previous NorPD study among children and adolescents (81). In that study, inhaled asthma 
drugs were included: Short-acting (SABA) and long-acting (LABA) inhaled 2-agonists; 
inhaled corticosteroids (ICS); and fixed dose combinations of 2-agonists and corticosteroids 
(FDC). In paper I-IV of the present thesis, leukotriene receptor antagonists (LTRA) were also 
included in the proxy measure. LTRA has during the 2000s received increasing importance in 
asthma therapy, and may be used as the only controller drug instead of corticosteroids (5, 75). 
An increasing use of LTRA in Norway has been observed (87, 97). Thus, the most commonly 
used asthma drugs classes were included in the proxy and pooled together as one variable (see 
appendix IV for an overview of drug classes in ATC group R03 Obstructive airway diseases).  
 
The asthma drug classes included in the proxy are the mainstay of asthma pharmacotherapy 
according to guidelines and treatment recommendations (5, 65, 67, 75). Other drugs registered 
in Norway with indication for use in asthma include anticholinergics, cromoglicic acid, 
xanthine derivatives (theophylline), anti-IgE therapy (omalizumab), and oral corticosteroids. 
Virtually all those who received these other asthma drug classes had also received at least one 
of the drugs in the proxy measure during the same year (paper II), i.e. these other asthma 
drugs were used as add-on therapy.  
 
For paper II and IV, the definition of the proxy measure was further restricted by only 
including prescriptions with the specific reimbursement code for asthma. Thus, the 
reimbursement code was used as a substitute for diagnostic codes (see chapter 1.3.3 for details 
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about the reimbursement system). Except for these reimbursement codes, it is not mandatory 
for physicians to provide diagnostic information on prescriptions. Physicians may, together 
with the dosage information, provide information about the intended use of the drug and this 
is stored as a free text variable in NorPD. 
3.3 Study populations 
Table 1 summarizes the study populations and setting in paper I-IV. 
Table 1: Study populations and setting 
 Paper I Paper II Paper III Paper IV
Study population 
source 
MoBa pilot 
(birth cohort)
NorPD 
(prescription 
database)
YHS 2000-2003
(health survey)
NorPDa
(prescription 
database)
Area covered Norway Norway 5 of 19 counties Norway
Participation rate 61%b Mandatory 
inclusion for all 
Norwegian 
residents
86%c Mandatory 
inclusion for all 
Norwegian 
residents
Indivduals 
invited/included
MoBa children 
over 7 years of 
age
Idividuals filling 
prescriptions on 
asthma drugsd
All students in 
10th grade in 
each county
Idividuals filling 
prescriptions on 
asthma drugsd
Study design Validity Crossectional 
and cohort
Cohort Crossectional
Study population 
included in analysis
n=2,056 n=92,074e n=10,164 n=37,060f
Outcome measured 
in period
During 
2007-2008g
2005-2007 Janaury 2005 - 
July 2010
3 March 2009 - 
2 March 2010
age during outcome 
period (yrs)
7-8 2-29 17-27h 8-29
Abbreviations: MoBa, Norwegian Mother and Child Cohort Study; NorPD, Norwegian Prescription 
Database; PHC, Population and Housing Census; YHS, Youth Health Surveys.
b
 On pilot questionnaire.
g
 During 1-year period prior to completion date of the MoBa questionnaire.
d
 Only prescriptions with reimbursement for asthma were included.
f
 n=1,239,533 in the standard population (all PHC participants 29 years or less).
h
 15-17 years old in the year of YHS participation (2000-2003).
a
 The study population was identified from NorPD data for participants in the PHC conducted in 2001.
e
 In 2007 (different study population in each 1-year cross-section). 
c
 77% gave consent to data linkage.
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Paper I 
The study population was from the MoBa pilot questionnaire distributed to 3,394 mothers of 
7-year old children in MoBa. 2,056 respondents (61%) were included in the analysis of 
validity.  
Paper II 
The study population included all individuals aged 2-29 years in Norway during 2005-2007 
(n~= 1.7 million) who had filled at least one prescription for asthma drugs according to 
NorPD (n= 92,074 in 2007). Only prescriptions with reimbursement codes for asthma were 
included. Asthma drugs included were those defined as a proxy measure of asthma, see 
chapter 3.2. In the persistence analysis, 115 individuals who died during 2005-2007 were 
excluded. 
Paper III 
Participants from the YHS conducted during 2000-2003 in five Norwegian counties were 
included. The surveys from 2004-2005 were excluded to avoid overlapping time periods with 
NorPD data from 2004 onwards. 15,436 individuals were invited to participate and 13,309 
(86%) responded to the questionnaire. 11,947 (77%) gave consent to link data with other 
registers, signed the consent form and were registered with valid person identity number, 
participation year and county. From this study population 1,783 individuals were excluded 
(see Figure I in paper III for details) and 10,164 participants without prior use of hypnotics 
were included in analysis.  
Paper IV 
The standard population included all persons who participated in the PHC in 2001 who were 
29 years or less in 2009. The study population consisted of current asthmatics that were 
identified in the standard population by using the proxy measure for current asthma (see 
chapter 3.2). Included were those who had filled prescriptions for an asthma drug at least once 
in the year before and at least once in the year after the index date (3 March 2009). Only 
prescriptions with reimbursement codes for asthma were included. 
 19  
3.4 Study design 
Paper I 
Data on filled prescriptions for asthma drugs during one year in NorPD were compared to 
maternal reports on questionnaires from MoBa regarding: 1) asthma drug use during the 
previous year; 2) the presence of ever asthma, current asthma and asthma diagnosis. The 
MoBa questionnaire was distributed during March-June 2008 to children who had reached 7 
years of age. The mothers reported the date of questionnaire completion but for those with 
missing completion date, the return date of the questionnaire minus 5 days was used. Data 
from NorPD were extracted for the one-year and the three-year period prior to the completion 
date. Non-respondents to the MoBa questionnaire were also linked to NorPD data to assess 
the proportion among responders and non-responders filling prescriptions for asthma drugs. 
Paper II 
Use of asthma drugs as registered in the NorPD during 2005-2007 was studied. A 
combination of study designs was used. Prevalence, incidence and types of drugs used were 
analyzed as annual cross-sections among 2-29 year olds. The size of the source population 
(the age-specific Norwegian population) and the study population (asthma drug users) was 
therefore different for each annual cross-section. Persistence to drug use was examined as a 
cohort study of all asthma drug users in 2005 (i.e. prevalent users) that were followed during 
2006 and 2007.  
Paper III 
A cohort study of hypnotic use among YHS participants (2000-2003) was conducted by 
record-linkage to NorPD data (January 2004 - July 2010). NorPD data from 2004 was used to 
define of the main independent variable (asthma), while NorPD data from January 2005 - July 
2010 was used as outcome variable (hypnotic use). 10,164 individuals at risk of initiating (i.e. 
incident) hypnotic use during the outcome period were studied.  
Paper IV 
This was a one-year cross-sectional study of the occurrence of comorbidities among 
asthmatics participating in the PHC 2001. NorPD data were linked with PHC data and 
asthmatics were identified by filled prescriptions on asthma drugs. The outcome variable 
(presence of comorbidity, yes/no) was defined from reimbursement codes on filled 
prescriptions (ICD-10 or ICPC-2 codes) that corresponded to selected comorbidities during a 
 20  
one-year period. The rate of occurrence of each comorbidity in the asthma population was 
compared to that in the standard population (all participants in PHC).  
3.5 Outcome variables 
The outcomes measured in paper I-IV were all defined by filled prescriptions in NorPD 
(Table 2). In paper I, maternal reports on questionnaire were also used.  
Table 2: Summary of outcomes measured in paper I-IV. 
 Paper Domain 
measured
Outcome 
measure
Definition Variable 
type
Filled prescription during a 1-year perioda Yes / no
Maternal-reported asthma drug use during 
 previous yearb
Yes / no
Maternal-reported ever, current and 
 physician-diagnosed asthma 4 categories
Prevalence 
proportion Filled prescription during calendar year Yes / no
Incidence 
proportion
Filled prescription during calendar year after 
 a run-in period with no filled prescriptionc
Yes / no
Persistence to 
treatment
Filled prescriptions in 3 consecutive 
 calendar-years Yes / no
Drug types 
used Filled prescription during calendar year 4 categories
Incidence 
proportion Filled prescription during calendar year Yes / no
Incidence rate 
ratio Number of filled prescriptions Count
Cumulative 
hazard Time to event (filled prescription) Continous
IV Comorbidity
Standardized 
Morbidity Ratiod
Filled prescription with specific diagnostic 
 code during a 1-year period Yes / no
d
 Calculated separately for nine chronic diseases and for antimicrobial treatment.
b
 Also examined reports on open-ended questions about names of specific asthma drugs used.
a
 During the 1-year period prior to the completion date of MoBa questionnaire. Also examined 
  the 3-year period prior to the completion date.
c
 Filled prescription during calendar-year and no filled prescription in previous 3 calendar-years.
III
I
Sensitivity 
and 
specificty
Asthma drug 
use and asthma
Asthma drug 
use
Hypnotic use
II
 
Paper I 
Use of asthma drugs as recorded in NorPD was compared with maternal reports about asthma 
drug use and asthma disease on the MoBa questionnaire. Included asthma drugs from NorPD 
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are given in chapter 3.2. Measures of validity were sensitivity and specificity. Positive 
predictive value and negative predictive values were also calculated. The MoBa questionnaire 
is included in appendix I. 
Validity of maternal reports of asthma: 
Maternal reports of asthma drug use in the MoBa questionnaire was compared to filled 
prescriptions on asthma drugs recorded in NorPD (reference standard). Use of asthma drugs 
in MoBa was defined by answers from mothers to the question “has the child used spray, 
inhaler or other medications for asthma during the past year?’’ (yes/no).  We examined the 
congruence between answers on this question and filled prescriptions in NorPD during the 
one-year and the three-year period prior to completion of the questionnaire. Maternal reports 
on open-ended questions about the name of asthma drugs used regularly or during attacks 
were also compared to NorPD data (salbutamol and fluticasone analyzed).  
Validity of asthma drug prescriptions as a proxy for asthma: 
Filled prescriptions for asthma drugs as a proxy measure of current asthma was compared to 
maternal reports of asthma disease in MoBa (reference standard). Asthma was defined in 
MoBa by mothers reporting on the question ‘‘has the child ever experienced any of the 
following long-lasting illnesses or health problems?’’. For each condition listed, the mothers 
ticked whether the child had ever experienced the condition, if the child still had the 
condition, and if a physician had verified it. Based on answers to these three questions we 
classified the participants into four mutually exclusive groups (see appendix III). NorPD data 
on prescriptions filled during the one-year and three-year period prior to completion of the 
MoBa questionnaire were used. Both children with and without filled prescriptions were 
included in the validity estimations.  
Paper II 
The outcome of interest was the use of any of the asthma drugs included in the proxy measure 
of current asthma, see chapter 3.2. Use of the asthma drugs was defined as filling 
prescriptions during 2005-2007. Four measures of drug use were calculated: two measures 
with the age-specific Norwegian population as denominator (prevalence and incidence 
proportions), and two measures with all prevalent asthma drug users during one year as 
denominator (persistence and type of asthma drug used). 
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Prevalence proportion: 
Prevalence proportion was measured as a series of one-year cross-sections (2005-2007) where 
the nominator was individuals filling at least one prescription on asthma drugs during each 
year. The denominator was the gender- and age-specific Norwegian population in each year 
(midyear population). The prevalence proportion filling at least two prescriptions (on different 
dates) during the one-year periods was estimated as well. 
Incidence proportion: 
We estimated incidence proportion by counting new users in 2007. New users were persons 
with no filled prescriptions in 2004-2006 and with at least one prescription in 2007 (drug-free 
run-in period of 3 calendar years (98)). The denominator (“population at risk”) was the 
gender- and age-specific Norwegian population as of 1 January 2007, minus individuals who 
had filled prescriptions during the previous 3-year period (2004–2006). 
Persistence: 
Persistence to treatment was assessed according to the minimum refill model (99). It was 
estimated as the proportion of the prevalent asthma drug users in 2005 being persistent to 
drug use the two subsequent years. The criterion for being categorized as “persistent” was: 
Filling at least one prescription in 2006 (1-year persistence), and at least one prescription in 
both 2006 and 2007 (2-year persistence). 
Type of asthma drugs used: 
Users of asthma drugs in each calendar year were classified by type of drug used. Individuals 
who received more than one type of asthma drug was assigned to the asthma drug group with 
the higher rank (i.e. groups were mutually exclusive): Inhaled 2-agonists (IBA), inhaled 
corticosteroids (ICS), Fixed dose combinations of 2-agonists and corticosteroids (FDC) and 
Leukotriene receptor antagonists (LTRA) (highest rank). The proportion of all prevalent users 
in each group was calculated. 
Paper III 
We studied initiation of hypnotic drugs use during January 2005–July 2010 among 
individuals without previous use of hypnotics (i.e. incident or new users). Hypnotic drugs 
were pooled together as one outcome variable and defined as: Benzodiazepines classified as 
hypnotics (ATC code N05CD), and the z-hypnotics zopiclone and zolpidem (N05CF). Three 
risk measures of the outcome were estimated. 
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Incidence proportion: 
Incidence proportion was estimated as the proportion of the study population filling 
prescriptions during follow-up (dichotomous variable of 0 prescriptions versus 1 or more 
prescriptions).  
Incidence rate ratio: 
Incidence rate ratio was estimated with a count variable of number of prescriptions filled 
during follow-up. Recurring events were examined, i.e. individuals remained at risk of filling 
another prescription after their first prescription.  
Cumulative hazard: 
Cumulative hazard was estimated with all prescriptions filled on different dates included 
(multiple recurring events).  
Paper IV 
Diagnostic codes from reimbursed drug prescriptions registered in NorPD were used to define 
the outcome (comorbid diseases). The presence of a disease was defined as filling at least one 
reimbursed prescription with a diagnostic code during a 1-year period (confer chapter 1.3.3 
for details on the reimbursement system). Nine chronic diseases were examined: Attention 
Deficit Hyperactivity Disorder (ADHD, denoted “hyperkinetic disorder” in ICD-10 and 
ICPC-2), epilepsy, migraine, mental illness, cardiovascular disease, diabetes (type 1 and 2), 
autoimmune disorders, gastro-oesophageal reflux disease (GORD) and allergy. See Table 1 in 
paper IV for details on diagnostic codes included. Outcome was measured by Standardized 
Morbidity Ratios (SMR). 
 
To study the occurrence of antimicrobial treatment (normally not reimbursed), ATC codes on 
drugs dispensed were used instead of diagnostic codes. Antibacterials recommended in 
Norwegian guidelines(100) for use in upper and lower respiratory tract infections were 
included, as well as antivirals used for influenza virus infections. See Table 1 in paper IV for 
details on ATC codes included. 
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3.6 Strata and independent variables 
Paper I 
Stratified analysis was not performed but all children had turned 7 years of age the year 
before the MoBa questionnaires were distributed and completed.  
Paper II 
All four measures of asthma drug use were stratified by gender and one-year age groups. For 
presentation in tables, age groups were collapsed into five groups.  
Paper III 
Asthma was the main independent variable. In the YHS, participants were asked “have you, 
or have you had asthma” with answer alternatives yes or no. This information was combined 
with the proxy measure for current asthma, operationalized as filling at least one prescription 
on asthma drugs during 2004 (see chapter 3.2 for details). Hence, receiving asthma drugs in 
2004 was used as a proxy measure of whether asthma was active (current) in the year prior to 
the start of follow-up. Individuals were classified into one of four asthma groups, see Figure 1 
in paper III: 1) no asthma (reference group); 2) not active asthma; 3) active asthma recently 
developed; 4) still active asthma. Other independent variables that were adjusted for in 
incidence rate ratio estimation were self-reported on the YHS questionnaire: Age, gender, 
mental distress (Hopkins Symptom Check List (HSCL-10) mean score), eczema, smoking 
habits, alcohol consumption, and plans for education. 
Paper IV 
The proxy measure for current asthma (see chapter 3.2) was used to define the study 
population of current asthmatics and was compared to the general population. Results were 
stratified by gender and two age groups (8-19 years, 20-29 years).  
3.7 Statistical analyses/methods 
Data preparation and statistical analyses were performed by using Spss 14.0.1 and 17.0.1 and 
Stata SE 9.2 and 10.0 for Windows.  
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Paper I 
95% confidence intervals were calculated for the validity measures by the continuity-
corrected score interval method (101). 
Paper II 
Not applicable. 
Paper III 
The asthma groups were introduced as three dummy variables with the ‘no asthma’ group as 
reference in the incidence rate ratio and cumulative hazard estimation. Incidence rate ratios 
were estimated by negative binomial regression, which account for higher variance than 
expected in the Poisson model. In the adjusted model, mental distress (HSCL-10), eczema, 
education plans and gender were entered as dichotomous variables and smoking, alcohol 
consumption and age as continuous variables. Cumulative hazard estimates for asthma groups 
were constructed by using Anderson and Gill’s method for defining time to event in recurrent 
events data, taking into account the dependency between recurring prescriptions filled by one 
individual (102). 
Paper IV 
The number of comorbidities occurring in the asthma population and in the general population 
was examined and presented as the proportion of the populations having respectively 0, 1, 2, 
3, and 4 or more comorbidities. Associations of asthma with specific comorbidities were 
examined by calculating Standardized Morbidity Ratios (SMR). Standard rates for 1-year age-
specific groups in the general population were calculated and applied to the asthma population 
separately for males and females. SMRs were calculated with 95% confidence intervals from 
the Poisson distribution. The magnitude of the SMRs are not directly comparable between the 
different genders and age groups, because they are compared to different standard 
populations. 
3.8 Ethical considerations 
The studies were endorsed by the Regional Committee for Medical Research Ethics and data 
linkage was approved by The Norwegian Data Inspectorate. The Research Council of Norway 
funded this work (project number 175314/v50). 
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4 SYNOPSIS OF PAPERS 
 
4.1 Paper I 
Furu K, Karlstad Ø, Skurtveit S, Håberg SE, Nafstad P, London SJ, Nystad W. High validity 
of mother-reported use of antiasthmatics among children: a comparison with a population-
based prescription database. Journal of Clinical Epidemiology 2011;64:878-84.  
Objectives 
1. To examine the validity of maternal reports of asthma drug use on a questionnaire from the 
Norwegian Mother and Child cohort study (MoBa), and  
2. To examine the validity of dispensed asthma drugs in the Norwegian Prescription Database 
(NorPD) as a proxy measure of asthma.  
Materials and methods 
Mothers of 2,056 7-year old children in MoBa responded to a pilot questionnaire (61% 
response rate). Data from NorPD was linked to both responders and non-responders of the 
questionnaire. NorPD data on dispensed asthma drugs served as reference standard for aim 1, 
while maternal reports of asthma in MoBa served as the reference standard for aim 2. 
Results 
• The one-year prevalence of having been dispensed asthma drugs in 2008 (NorPD) was 
7.6% among responders and 7.9% among non-responders. 
Aim 1: 
• The sensitivity of the indication-specific MoBa question about asthma drug use during the 
previous year was 85%, compared to NorPD data on dispensed asthma drugs during same 
period (reference). The specificity was 97%. 
• Among 61 children who had no dispensed drug in the previous year despite mother-
reported use, 52% had been dispensed drugs 1-3 years ago. 
• Open-ended questions about names of asthma drugs used had lower sensitivity (salbutamol 
72%; fluticasone 74%) and higher specificity (salbutamol 98%; fluticasone 99%). 
Aim 2: 
• Current asthma was reported in 6.5% of children while current and physician-diagnosed 
asthma was reported in 5.9% of children (MoBa). 
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• The sensitivity of dispensed asthma drugs during the previous year (NorPD) to identify 
children with current and physician-diagnosed asthma (MoBa) was 80%. 
• The sensitivity was 55% for current but not physician-diagnosed asthma, and 18% for 
asthma in the past. 
• Only 1.2% of children with no reported asthma had been dispensed asthma drugs in the 
preceding year. 
• If the data extraction period for NorPD was extended from the previous year to previous 
three years, sensitivity increased and specificity decreased.  
Conclusions 
Mother-reported use of asthma drugs during the previous year among children was highly 
valid compared with records of dispensed drugs as reference standard. Prescription data on 
dispensed asthma drugs could be a useful proxy for identifying individuals with current 
asthma in the population.  
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4.2 Paper II 
Karlstad Ø, Nafstad P, Tverdal A, Skurtveit S, Furu K. Prevalence, incidence and persistence 
of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. 
European Journal of Clinical Pharmacology 2010;66:399-406.  
Objectives  
To explore asthma drug use in the entire Norwegian population aged 2–29 years during 2005–
2007 by examining: The gender- and age-specific annual prevalence and incidence of asthma 
drug use, and the proportion of asthma drug users persistent to treatment for 3 years, and the 
type of asthma drugs used. 
Materials and methods 
Data were retrieved from the Norwegian Prescription Database (NorPD) for all individuals 2–
29 years old who received asthma drugs with reimbursement for asthma during 2005–2007.  
Results  
Prevalence and incidence: 
• The annual prevalence was relatively stable during 2005-2007. 
• Annual prevalence in 2007 of receiving drugs once was 5.9% (males) and 5.0% (females), 
while prevalence of receiving drugs at least twice was 3.4% (males) and 2.7% (females). 
• Incidence of receiving asthma drugs in 2007, with three calendar years of drug-free run-in 
period, was 1.5% in both males and females. Incidences increased to 2.3% and 1.7% when 
the run-in period was shortened to one and two years, respectively. 
• For both genders, the general trend by age was a decrease from the highest levels in 2-year 
olds to lowest levels in 20-29 year olds. During adolescence, an increase was observed 
among females that was not observed in males.  
• Males had higher prevalence and incidence levels in the youngest age groups but levels for 
females surpassed males at 14-16 years of age. 
Persistence to treatment: 
• Among individuals who received asthma drugs in 2005, 61% also received drug in 2006, 
while 45% received drug in both 2006 and 2007. 
• 10% received drug in 2005 and 2007 without receiving drug in the intervening year (2006). 
Type of asthma drug used: 
• The type of asthma drug received was substantially different by age but not by gender. 
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• A high share of preschool children were on ICS treatment (69%), shifting gradually to high 
shares on FDC (42%) or IBA monotherapy (35%) in 20-29 year olds. 
• The share of all asthma drug users who did not receive any asthma controller drug (ICS, 
FDC or LTRA) increased from 14% in preschoolers to 35% in 20-29 year olds.  
• 39% of LABA users in 2007 did not receive any inhaled corticosteroids (ICS or FDC) 
during the three preceding calendar years. These individuals constituted 1.5% of all asthma 
drug users in 2007. 
Conclusions 
Annual prevalence of asthma drug use in 2-29 year olds was stable during 2005–2007. The 
gender- and age-specific profile of prevalence and incidence correspond well with studies of 
asthma prevalence and incidence. Fewer than half the individuals filled prescriptions regularly 
over a 3-year period. The type of asthma drugs used was substantially different by age, with a 
gradual shift from ICS treatment in preschoolers to FDC or IBA monotherapy in older age 
groups. 
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4.3 Paper III 
Øystein Karlstad, Aage Tverdal, Svetlana Skurtveit, Per Nafstad and Kari Furu. A prospective 
study of asthma and subsequent use of hypnotics in young adults. Pharmacoepidemiology and 
Drug Safety 2011;20:370-7.  
Objectives/ 
To investigate whether young adults with asthma are at higher risk of initiating use of 
hypnotics. 
Materials and methods 
10,164 (86% response rate) 15-17 year olds from the Youth Health Surveys (YHS) with no 
previous use of hypnotics were linked to the Norwegian Prescription Database (NorPD). Four 
asthma groups were defined based on self-reported asthma (YHS) and asthma drug use 
(NorPD). The outcome was filling prescriptions on hypnotics during January 2005 – July 
2010. Incidence proportions, Incidence rate ratios (IRR) and cumulative hazards were 
estimated. IRR was adjusted for potential confounders (illnesses, lifestyle and 
sociodemographic factors).   
Results 
• The incidence proportion was 6.1%, ranging from 5.7% in the no asthma group to 9.5% in 
active recently developed asthma group.  
• The crude IRR was 1.35 (CI: 0.93–1.95) for not active asthma, 4.18 (1.83–9.55) for active 
recently developed asthma, and 1.63 (0.85–3.14) for still active asthma (no asthma group 
as reference).  
• Adjusted IRR for active recently developed asthma group changed to 4.72 (2.07–10.75) 
while the other groups remained statistically not significant.  
• Cumulative hazard functions were significantly different for the four groups, with highest 
hazard for the still active asthma group early on, but surpassed by the active recently 
developed asthma group after about 3 years of follow-up. 
• Results were robust towards changes in study design and statistical methods. 
Conclusions 
In this prospective study of young adults in a general population setting, asthmatics had an 
increased risk of initiating hypnotic use. We observed a substantial differences in risk 
between asthma groups, with higher risk among asthmatics who recently received asthma 
drugs.  
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4.4 Paper IV 
Karlstad Ø, Nafstad P, Tverdal A, Skurtveit S, Furu K. Comorbidities in an asthma population 
8-29 years old - a study from the Norwegian Prescription Database. Manuscript accepted for 
publication in Pharmacoepidemiology and Drug Safety, July 2011. 
Objectives  
To examine occurrence of chronic diseases and antimicrobial treatment (comorbidities) in an 
asthma population 8-29 years old, compared to the occurrence in the Norwegian population.  
Materials and methods 
The asthma population was identified by dispensed asthma drugs in the Norwegian 
Prescription Database (NorPD). The occurrence of nine chronic diseases (comorbidities) was 
identified by received prescriptions with specific diagnostic codes (reimbursement codes) 
during one year: ADHD, epilepsy, migraine, mental illness, cardiovascular disease, diabetes, 
autoimmune disorders, GORD, allergy. Antibacterials for respiratory tract infections and 
antivirals were examined by drug class identification (ATC codes). Standardized Morbidity 
Ratio (SMR) for each comorbidity in the asthma population was calculated from the age-
specific general population. 
Results 
• 59% of asthmatics had at least one of nine chronic comorbidities examined, compared to 
18% in the general population.  
• 6% of males and 8% of females had more than one of the chronic comorbidities.  
• When antimicrobial treatment was included, 69% (male) and 71% (female) asthmatics had 
at least one comorbidity, compared to 30% and 34% in the general population. 
• SMR estimates were consistently increased in both age groups and genders for all diseases 
except diabetes (range 0.9-1.4). 
• Allergy and GORD had highest SMR (range 3.2-4.8) while the other comorbidities were in 
the range 1.2-2.5.  
Conclusions 
By using a nationwide prescription database containing diagnostic codes on reimbursed 
prescriptions, an excess occurrence of comorbidities in the young population of asthmatics 
was observed, compared to the general population of Norway. A majority of asthmatics had 
one comorbidity, while few had more than one. 
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5 DISCUSSION 
5.1 General discussion 
5.1.1 Use of asthma drugs  
The prevalence of asthma drug use was stable during 2005-2007 among 2-29 year olds and 
was 5.5% in 2007 (paper II). For children and adolescents, our prevalence estimates are in the 
lower end compared to other studies: High levels (12-26%) have been reported in Italy and 
the USA (84, 103-105), while lower levels (4-8%) have been reported in the Netherlands, 
Denmark and the UK (36, 83, 85, 106, 107). In adults 20-29 years old, we found a stable 
prevalence during 2005-2007 that was 3.3% in males and 4.3% in females in 2007 (paper II). 
There are few studies among adults on the prevalence of asthma drug use. A Swedish study 
found a prevalence of 4.2% (males) and 5.9% (females) for any drug from ATC group R03 in 
18-44 year olds in 2007 (108). A study from the European Community Respiratory Health 
Survey (ECRHS) reported a one-year prevalence of self-reported asthma drug use in 
Norwegians 20-48 year olds to be 3.6% (1990-1994), increasing to 7.7% (1998-2003) (80). 
The overall prevalence for all 14 countries of this ECRHS study was 6.8% (1990-1994) and 
9.5% (1998-2003). 
 
The aforementioned studies from different countries give crude numbers indicating which 
countries have higher and lower levels of asthma drug use. However, differences in age 
groups and definition of asthma drugs have great impact on the level of the prevalence 
estimates. For example, some studies included all drugs in ATC group R03 while other 
studies applied some reasoning to select specific respiratory drugs. Furthermore, some studies 
had access to diagnostic codes and confined populations to patients with physician-diagnosed 
asthma. Thus, it is likely that the study populations are heterogeneous.  
 
The gender- and age-profile of asthma drug use in children and adolescents shows highest 
prevalence among the youngest age groups. Males had higher prevalence until adolescence, 
when an increase in prevalence is present in females and surpasses males from about 15-16 
years onwards. The profile was stable during 2005-2007 (paper II) and the same pattern was 
also found in 2004 (81). Furthermore, the same profile emerges when including only persons 
who had two or more prescriptions, as when including persons who had one or more 
prescriptions (see appendix IV). This gender- and age-profile of asthma drug use has been 
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reported in Canada, the Netherlands and the UK, but not in Italy (84, 109, 110). These data on 
asthma drug corresponds well with studies of gender differences by age in the occurrence of 
asthma (48, 111-113).  
5.1.2 Type of asthma drugs used 
We studied the type of asthma drugs used by the Norwegian population 2-29 years of age in 
paper II. The assignment of asthma drug users to four mutually excluding drug groups may 
“preclude” some patterns of use. For example, inhaled corticosteroids (ICS) or fixed dose 
combinations of 2-agonists and corticosteroids (FDC) may have been used in the leukotriene 
receptor antagonists (LTRA) group as well, and shares in the ICS and FDC groups should be 
regarded as the minimum using inhaled corticosteroids. Nonetheless, paper II gives and 
overview on asthma drug use of the entire young Norwegian population. The apparent use of 
inhaled long- and short-acting 2-agonists (LABA and SABA) as monotherapy is discussed 
further below.  
 
The safety of using LABA as monotherapy for asthma has been debated since the early 2000s 
(114-116).  Regulatory agencies and guidelines state that LABA should only be used in 
combination with controller drugs like ICS (5, 75, 76). In paper II, we found that 39% of 
patients who received LABA during 2007 (1.5% of all asthma drug users) had not received 
any inhaled corticosteroids as controller drugs during 2005-2007. Taking use of LTRA into 
account only slightly reduced the share (38%, new unpublished data). Similar results to our 
finding have been reported for young adults in other countries; LABA monotherapy varied 
from 18-37% in Swedish counties, while it was reported in 26% and 11% of two American 
populations (108, 117, 118). The data in paper II are from 2007 and the use of controller 
drugs may have improved since then as the warnings from drug regulators intensified. 
Furthermore, the length and intensity of such monotherapy may be important but this was not 
investigated in our study. Further studies on the pattern and determinants of LABA 
monotherapy are warranted.  
 
Another finding in paper II was the apparent use of SABA as monotherapy in a large share of 
adolescents and young adults: The share was 14% in preschoolers and increased to 35% in 20-
29 year olds. This may reflect underuse of long-term controller drugs such as ICS. A few 
studies from Northern Europe have investigated SABA monotherapy and intensity of such 
use. Uijen et al. reported that 35% of 0-17 years olds on asthma therapy received SABA as 
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monotherapy (119). Davidsen et al. reported that nearly 20% of young adults with high 
consumption of inhaled 2-agonists (IBA) did not receive ICS, with higher shares among low 
IBA consumers (120). Arnlind et al. reported uneven use of IBA (mostly SABA) among 
young adults, with a large share of doses being consumed by a small share of the patients 
(108). Paper II only gives crude data and SABA monotherapy is warranted in patients with 
mild, intermittent asthma (5). SABA may also have been used once as part of diagnosing 
respiratory complaints and some patients may have leftover controller drugs from previous 
years. A study of the intensity (doses and length of use) and determinants of SABA 
monotherapy is warranted, taking into account use of other asthma drugs. Furthermore, the 
intensity of SABA consumption may be used as a marker of asthma control in future studies 
(121, 122).  
 
Our findings indicate that the pharmacotherapy of asthma may not be optimal, and could be 
due to concerns among patients or parents regarding long-term use of corticosteroids. Asthma 
therapy may be improved by educating patients on the safety, benefits and the place in 
therapy for the different asthma drug classes.  
5.1.3 Reported asthma drug use compared to prescription data 
Maternally reported asthma drug use in 7 year old children was studied for both an indication-
specific drug question and for an open-ended question regarding the name of drugs (paper I). 
We found relatively high sensitivity (85%) and specificity (97%) for the indication-specific 
question, compared to filled prescriptions during the last year as reference standard. 
Furthermore, about half of the false positives had in fact received drug prescriptions, but did 
so 1 to 3 years ago. These children may have had intermittent asthma and had drugs left from 
earlier treatment episodes, with consequently no need to fill prescriptions during the last year. 
It may also represent some recall problems as to the exact time children used the drugs during 
the last 3 years. Our results correspond well with a Danish study among 6-8 year-olds 
reporting 92% sensitivity and 96% specificity (123). A previous study from the Norwegian 
Youth Health Surveys in 15-16 year olds reported a lower sensitivity (75%) on the asthma 
drug use question (124). This may be related to a lower adherence in adolescents, or 
differences in phrasing of questions and the age group that is reporting. On the open-ended 
questions regarding the names of the asthma drugs used we found lower sensitivity (range 72-
74%) but high specificity (range 98-99%) compared to the indication-specific question. This 
is in accordance with published literature on phrasing of drug use questions (2). 
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5.1.4 Asthma drug use as a proxy measure for asthma 
Administrative data on drug use may be utilized as a proxy measure of the occurrence of 
some diseases in the population. Generally, this is feasible if the drugs are used exclusively 
for one disease (specific) and that all diseased use drugs (sensitive). Insulin used by children 
with diabetes type 1 is probably the best example. We examined the validity of filled 
prescriptions on asthma drugs as a proxy measure of asthma in paper I. This proxy measure 
was utilized to identify current asthmatics in the study populations of paper II-IV.  
 
There is no agreed upon gold standard for defining asthma in epidemiological studies (28). In 
paper I, maternal reports on a questionnaire regarding asthma in their children were used as 
reference standard (alloyed gold standard (2)). The children with no reports of asthma by their 
mothers were correctly identified by the proxy as not using asthma drugs in the previous year 
(1.2% received drugs) and the previous three years (3.7%, new unpublished data). The ability 
of the proxy measure to identify children with “current, physician-diagnosed asthma” was 
relatively high (sensitivity 80%) but may reflect some under-treatment. Alternatively, the 
capture period of one year in NorPD may be too short to capture all children deemed by their 
mothers to have current asthma, especially those with seasonal or intermittent asthma. This is 
supported by the improved sensitivity when increasing the length of the capture period (94% 
for three years). The proxy was less valid for identifying the two other categories of 
asthmatics (“current but not physician-diagnosed asthma” and “asthma in the past”). These 
two asthma groups are probably heterogeneous, with some individuals who should have 
received drugs and others that should not. Thus, a 100% match between questionnaire and 
prescription data was not expected. It is difficult to interpret the information that lies in 
mothers reporting “current but not physician-diagnosed asthma” and only 11 children were in 
this group. It could include some cases of mild asthma or cases still in the diagnostic process. 
For the group who had “asthma in the past”, 18% had used drugs in the past year while 56% 
(new unpublished data) had used drugs in the past three years. 
 
International studies have shown the feasibility of using databases with prescriptions as a 
proxy measure for asthma among children and adolescents (36, 107), and adults (34). 
Different cut-offs for the number of prescriptions received, length of capture period of 
prescriptions, and choice of asthma drugs to include in the proxy measure have been analyzed 
to identify the best-performing proxy measure. These studies used diagnosed asthma, 
retrieved from physicians, as a dichotomous reference standard. The best-performing proxy 
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measure using one year of prescription data had sensitivities between 63% and 95%, while 
specificities were between 87% and 99% (34, 36, 107).  It is important to view these result in 
light of the differences in health care systems, reimbursement schemes and prescribing 
practices between countries. These factors influence how intimately linked asthma drug 
prescriptions is to the occurrence of asthma, and results may not be transferable to a 
Norwegian setting. In Norway, factors such as a well-developed government-financed 
healthcare system, a high rate of practicing physicians per inhabitants, and low co-payment 
for reimbursed drugs and physician visits (see chapter 1.3.3) should ensure that asthmatics 
have good access to asthma treatment.  
 
Our validation study was carried out among mothers of 7-year old children, and the mothers’ 
ability to report should not be substantially changed as children age. However, the proxy 
measure may not be transferable to all age groups. It is difficult to diagnose asthma in 
children less than 5 years of age because of variable and non-specific clinical symptoms, 
while airflow limitation and inflammation is difficult to assess (5, 12, 13). Asthma drugs are 
probably used during episodes of other respiratory complaints in preschool children who do 
not have asthma (106), or who have transient asthma complaints that will not persist into 
school age (7, 9). In adults, both an overlap in diagnosis and drug treatment with COPD will 
occur and the proxy measure may not be used above 40-50 years of age (12). The validity of 
this proxy measure is probably best in adolescents and young adults, because overlapping 
conditions are less prevalent and lung function testing as part of diagnosis is possible. Some 
mild cases are probably not captured by this proxy measure, as they are more difficult for 
physicians to detect, diagnose and subsequently prescribe drugs. However, the continuous 
data collection over several years may enable us to identify individuals who have long periods 
with remission of asthma (i.e. not used drugs for longer periods). A problem in asthma 
epidemiology is the transient nature of the disease in many patients, and there are no criteria 
for diagnosing the resolution of asthma. The same individual may switch from being regarded 
as asthmatic to nonasthmatic depending on when information is collected (28). Asthma 
should be regarded as a continuum rather than a dichotomy, and may be a syndrome arising 
from several pathways (125, 126). Thus, longer follow-up than one year is needed to separate 
cases of complete remission from cases in a temporary quiescent state. In the incidence and 
persistence analysis (paper II), 3-4 years of NorPD data was utilized. The results may reflect 
some of the variability of asthma disease, but a study using a longer follow-up period is 
desirable.  
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NorPD can identify current asthma that requires drug therapy in the population, given these 
restrictions on age. In paper I, the proxy measure using a one-year capture period performed 
best in identifying children with no reported asthma (specificity), while increasing the capture 
period to three years gave a good sensitivity. The definitions of the proxy measure can be 
varied depending on the focus of interest and will be a trade-off between high sensitivity and 
high specificity (32). Changes in the length of the capture period, drug classes included, and 
number of prescriptions required, may give different prevalence of asthma (127) and some 
advocate the use of positive predictive value to evaluate the proxy measure (107). For the 
NorPD data, it is possible to restrict the proxy measure by using reimbursement codes on 
prescriptions as a substitute for diagnosis. This has been done in a previous NorPD study (81) 
and was applied in paper II and IV.  
 
The use of the question “ever asthma” in paper III could be problematic because of the 
variation in the disease activity and persistence of asthma over time. Sleep problems and use 
of hypnotic drugs (the outcome of the study) has been linked to the level of asthma control, 
i.e. currently active asthma. We therefore supplemented the questionnaire data with data on 
filled prescriptions for asthma drugs as an indication of whether asthma was currently active 
in the year prior to start of follow-up. 
5.1.5 Comorbidities of asthma 
In paper III and IV, we examined additional health problems and diseases requiring medical 
treatment that occurred in asthmatics in populations of children, adolescents and young adults.  
 
Paper III showed a substantially higher risk of initiating hypnotic use in young adult 
asthmatics, especially in those who recently were in active asthma treatment. Results were 
robust towards the changes in design and statistical methods that we applied. The adjustment 
for covariates had little impact on risk estimates and may reflect that the measured covariates 
do not influence the effect of asthma group on risk of hypnotic use. Caution is warranted 
when interpreting this as covariates were measured a few years before the start of follow-up. 
This was during late adolescence, where changes in behaviors such as smoking and alcohol 
use occur in many individuals. The increased risk of hypnotic use could be a direct 
consequence of low asthma control, leading to more frequent or severe symptoms (e.g. 
nighttime symptoms). The level of control of asthma symptoms is related to both sleep 
 39  
problems (63, 128, 129) and hypnotic use (130). It could also be a secondary effect of one of 
the many comorbidities observed in asthma populations (53, 131-133), which can have 
detrimental effects on sleep (e.g. allergy, depression and anxiety (53, 64, 128, 134-137)). We 
examined the occurrence of allergy, depression, anxiety as well as other chronic diseases 
among asthmatics in paper IV.  
 
We found a higher occurrence of several chronic diseases among asthmatics in paper IV. This 
is the first study to examine asthma and comorbid diseases in the entire Norwegian population 
by using the diagnostic codes from NorPD. We studied chronic diseases that have been 
associated with asthma in previous population-based studies (53, 131-133) that were expected 
to be of some magnitude in this age group. Given the method for identifying comorbidities in 
this study, the diseases also had to have a relevant pharmacotherapy with reimbursement. A 
prerequisite for receiving reimbursement is that the physician deems the patient to have 
chronic disease (confer chapter 1.3.3).  Thus, our measure of comorbidity will capture chronic 
diseases diagnosed by a physician, where the physician and the patient have chosen to treat 
with drugs in the ambulatory setting. 
 
The observed associations may be due to causal pathways for development of disease, or be 
indirectly linked through common genetic and environmental factors. Some of the relations 
between asthma and comorbidities (allergy, GORD, infections) have been widely studied, and 
allergy may even be regarded as part of the asthma disease complex (atopic asthma 
phenotype). A multitude of possible biologic mechanisms could explain the observed 
associations. However, the process for developing asthma is not fully understood and there 
are few confirmed risk factors for asthma (9, 16, 73). Our study (paper IV) was cross-
sectional, which precludes any inferences about the temporal sequence of developing asthma 
and comorbidities. Furthermore, the data and design is not suitable for making inferences 
about biology. A final observation regarding the results of paper IV is that many of the 
absolute differences are quite small and few had more than one of the comorbidities studied. 
This reflects the young and still relatively healthy population studied.  
 
A contributing factor to the increased occurrence of additional health problems in asthmatics 
that was observed in paper III and IV could be detection bias (2); asthmatics visit physicians 
more often than their healthy peers and additional health problems come to the attention of the 
physician. Detection bias is less likely to be the case for more severe diseases such as diabetes 
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type 1. Furthermore, this bias may work the other way around in paper IV; mild, undiagnosed 
asthma may be more readily detected in persons who have other reasons for visiting 
physicians.  
 
Another possible explanation is that asthmatics that are often in contact with their physician 
will likely be more aware of their illnesses and subsequently seek healthcare services. This 
relates to the issues on how to measure the occurrence of asthma and is not unique to studies 
based on healthcare service use. Self-reported asthma symptoms on questionnaires are 
commonly used in asthma epidemiology (21, 138). Reporting is influenced by the patients 
own perceptions and preferences, such as the threshold for reporting symptoms, seeking care 
and using drugs. For instance, psychosocial factors and mental illnesses like stress, depression 
and anxiety have been associated with asthma symptoms, but not necessarily with objective 
markers of asthma (e.g. lung function) or asthma diagnosis. These findings have been partly 
attributed to an increased perception of respiratory symptoms in patients with mental illnesses 
(135, 137, 139). Prescription data are objective in the sense that the individuals using drugs do 
not make deliberations on whether they have asthma symptoms. However, choosing to visit a 
physician and using the prescribed drugs rest on subjective judgments. 
 
Prospective studies that can disentangle the temporal sequences of events may give new 
insight. Furthermore, studies of the consequences of comorbidities related to asthma 
outcomes are needed (52, 54). Comorbid diseases can lead to diagnostic difficulties, less 
control of symptoms, modulate the severity, and alter the response and adherence to asthma 
therapy (52-56). Use of hypnotics among individuals with asthma may be related to the level 
of asthma control and improvements in asthma management can make a difference, and the 
identification and treatment of comorbidities is part of the core management of asthma (5).  
5.2 Methodological considerations 
This chapter pertains to general considerations in epidemiologic research that is relevant to 
our studies. Specific methodological issues regarding the measures of asthma and asthma 
drug use have been discussed in chapter5.1.4. 
 
The objective of epidemiological studies is to obtain an valid and precise estimate of the 
frequency of a disease/condition or of the effect of an exposure on the occurrence of a disease 
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(1). Furthermore, this estimate should be generalizable to a relevant target population. Thus, 
the study population should either be the target population itself, or at least experience effects 
similar to the target population. Errors that influence the estimate may be classified as random 
or systematic.  
 
Random errors influence the precision of the estimate and may be represented by the width of 
the confidence limits around the point estimate. Random errors will generally diminish if the 
study population size is increased and studies using NorPD as population source are generally 
large. Thus, problems with random error were considered to be small when drawing the study 
population from NorPD. The Youth Health Surveys (paper III) are relatively large (~15,000 
individuals invited). However, division of the study population by asthma groups yielded two 
small groups and will, together with the high number of zero counts (no filled prescriptions) 
in the outcome variable, contribute to less precise estimates in each group. The MoBa cohort 
study consists of more than 100,000 pregnancies but our study (paper I) was based on the 
children who had reached 7 years of age, thus constituting ~2000 respondents.  
 
Systematic error tends to be a greater problem than random error in epidemiological studies. 
It influences the validity of the estimate by producing results that are consistently distorted in 
one direction, and the validity may be separated in two components: Internal validity of the 
inferences as they pertain to the source population, and external validity (generalizability) of 
inferences as they pertain to people outside the population (1). Three types of systematic 
errors in observational studies will be discussed in the following sections: Selection bias, 
information bias and confounding. 
5.2.1 Selection bias 
Selection bias is due to the procedures for selecting subjects to be included in the study and 
factors that may affect participation in the study. Thus, participants may not be representative 
of the source population because the occurrence of disease or the exposure-disease association 
is different in participants and non-participants (1). The age group examined in paper I-IV 
were under 30 years of age and the effect of selective survival of healthier individuals was 
considered negligible. Individuals who died (paper III and IV and persistence analysis in 
paper II) and emigrated (III and IV) were excluded from analysis because they did not have 
the chance to get the outcome. Relatively few individuals were excluded and then mainly due 
to emigration.  
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For NorPD, there is mandatory registration in the database, thereby covering all persons 
residing in Norway who fill prescriptions (no self-selection issues). Few individuals at this 
age are permanently residing in institutions and NorPD should therefore cover virtually all 
drug users in Norway. The study population in paper II was defined by NorPD data and 
selection bias was considered negligible with respect to asthma drug use. The population in 
paper IV was also defined by NorPD data but restricted to the individuals participating in the 
Population and Housing Census in 2001. This was a census in the entire population with 
mandatory participation and selection bias in paper IV was considered negligible. The 
representativeness of the individuals defined as asthmatics by our measures in paper I-IV has 
been discussed in chapter 5.1.4. 
 
The MoBa cohort study (paper I) invited pregnant women from all over Norway to participate 
during 1999-2008, and the end of enrolment protocol released in 2010 (91) showed an overall 
participation rate of 38.5%. Nilsen et al. (140) studied the potential bias from self-selection in 
MoBa data from the period 2000-2006 (participation rate 43.5%), by comparing to all women 
giving birth in Norway. Nilsens study suggests that associations between exposures and 
outcomes were not biased but some prevalence estimates were. For example, the proportion of 
mothers that were smoking was lower in MoBa compared to total population, while 
prevalence of pregnancy complications and diseases were similar. Maternal asthma was about 
4% in MoBa participants and in the total population (140). For the specific questionnaire used 
in paper I, the response rate was 61%. Self-selection in responding to this questionnaire was 
assessed by comparing prevalence of asthma drug use in the children between responders 
(7.6%) and non-responders (7.9%) as recorded in NorPD. The prevalence in the Norwegian 
population of 7-year olds was lower (6.9%). Selection bias is probably less important in 
studies of correspondence between two data sources (paper I) than in studies of prevalence of 
disease. 
 
The Youth Health Surveys (paper III) invited all 10th grade students in each county and had a 
response rate of 86%, while 77% were possible to link with other register data. This is a 
relatively high participation rate, and may in part be attributed to questionnaires being filled 
out during school lessons. Students from some schools in Troms and Finnmark only received 
questionnaires by mail and had lower participation rate. However, also the school-based 
surveys in these counties had lower participation rates. In Oslo, Oppland and Hedmark, 
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reminders were sent to the home of non-responders. It is likely that no significant self-
selection bias has occurred (internal validity). The counties surveyed were from different 
geographical areas of Norway and include both urban and rural areas. The study population 
should be fairly representative of the young population in Norway (external validity). The 
prevalence of asthma drug use in the study population and the Norwegian population of the 
same age was similar, and this is an indirect assessment of selection bias. 
5.2.2 Information bias 
Information bias pertains to the accuracy of the information collected for different variables, 
and is also called misclassification when discrete variables are used (1). When the 
misclassification of variables is similar for all individuals, it is called non-differential. When 
the misclassification of one variable is dependent on the actual value of another variable (e.g. 
more misclassification of outcome variable among non-exposed than exposed), it is called 
differential. 
    
The use of drugs as registered in NorPD is central in all papers of this thesis. The terms fill or 
redeem prescriptions, receive or dispense drugs, have been interchangeably used with the 
term “drug use” throughout paper I-IV, and essentially mean filling a prescription at the 
pharmacy. Interpretation of “drug use” must take into account the possibility of received 
drugs not being used, or used at another time than it is received from the pharmacy. It seems 
less likely that drugs are not used if patients receive the same drugs on several occasions. 
Obtaining drug exposure data from databases such as NorPD eliminates recall bias (2). The 
electronic registration of data at the time of dispensing the drug as well as legislations and 
other incentives ensures high quality of registered data. Furthermore, NorPD captures all 
filled prescriptions to individuals in ambulatory care, regardless of reimbursement status, 
prescriber speciality or occupation (primary, secondary and tertiary care), or if patients move 
within the country. Asthma drugs (paper I-IV) and hypnotics (paper III) are prescription-only 
drugs and can be considered complete. Regarding paper IV, over-the-counter drugs are 
available for the treatment of allergy and GORD but patients have economic incentives to 
obtain a prescription and thereby receive reimbursement.  
 
The self-reported data used in paper I and III relies on respondents correctly interpreting the 
questions, recalling the information precisely and willingness to disclose the correct 
information. Furthermore, questions need to formulated and presented in an unambiguous 
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manner on questionnaires. For questions on drug use, the time frame for recollection is 
important as participants have more difficulties recollecting drug use in distant past. 
Additionally, drug class-specific or indication-specific questions on drug use have been found 
to give more accurate reports than open-ended questions on the names of drugs used (2). In 
the validation study (paper I), the recall period was one year for the asthma drug use question 
and was found to have high validity. We observed the aforementioned difference between 
open-ended and indication-specific questions in paper I. In paper III, the covariates for the 
Incidence rate ratio (IRR) analysis were self-reported (except age and gender). There is a 
potential for selective reporting according to social desirability (e.g. smoking and alcohol 
consumption), while recall bias should be less pronounced as most covariates measured the 
current status. However, they were measured some time before start of follow-up, and may 
have changed before or during follow-up. 
 
Possible detection bias in paper III and IV has been discussed in chapter 5.1.5. 
5.2.3 Confounding  
Confounding occurs when a secondary variable that is linked to both exposure and outcome 
distorts the estimate of effect, and may wholly or partially explain an observed association (1, 
2). Possible confounding variables were adjusted for in paper III by using multivariable 
analysis in IRR estimation. Adjustments had little impact on the risk estimates. This may be 
due to changes in measured covariates between the baseline survey and the outcome period, 
or that the measured covariates do not influence the effect of asthma group on risk of hypnotic 
use. Stratification by gender (paper II and IV), stratification by age (II), and age 
standardization (paper IV) were performed to observe differences by gender and age. 
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6 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
 
The prevalence of asthma drug use in the Norwegian population of children, adolescents and 
adults was relatively stable at about 5.5%, with higher rates in preschool children and lower 
rates in young adults. Both prevalence and incidence of drug use was higher in females from 
about 15 years of age. These data on asthma drug use corresponds well with the findings in 
epidemiological studies of asthma. We found good correspondence between reported asthma 
and asthma drug use registered in NorPD. Thus, NorPD could be a valuable proxy to identify 
active asthma diseases in the Norwegian population, given some restrictions on age groups 
and careful definition of the proxy measure. 
 
The incidence and persistence analysis indicates that a large share of asthma drug users did 
not use their drugs continuously over years. This variability reflects the fluctuations of asthma 
disease over time, which complicates the definition of asthma in epidemiological research. 
Although several potential risk factors for asthma have been identified, efforts in 
epidemiology and other research fields on asthma have not been very successful in identifying 
causal factors for asthma development. Therefore, preventive measures remain illusive, and 
asthma pharmacotherapy is concentrated on controlling symptoms and not remission of the 
disease. Part of the problem in identifying risk factors seems to be how to define asthma in 
population studies, with great variability in definition, time frame and entities of the disease 
being measured. A strength of the NorPD data is the continuous and complete collection of 
high quality data and gives a new opportunity in Norway to follow individual patients’ drug 
use over time. NorPD data could shed light on the natural history of asthma drug use, and the 
underlying disease, from childhood and into adulthood on a population-based scale by 
tracking patient cohorts over a longer time period. It would be interesting to further 
investigate whether there is a subgroup of patients that once they initiate drug use, need 
treatment consistently from childhood into adulthood.  
 
This study has provided evidence of other diseases and health problems that are 
overrepresented in asthmatics in the Norwegian population. Several chronic diseases and 
antimicrobial treatment occurred more frequently in asthmatics, while the risk of initiating 
hypnotic use was higher in asthmatics. In due course, it will be possible to assess the time 
sequence of occurrence of asthma and the other chronic diseases that we have studied. 
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The study of asthma drugs used by the Norwegian population revealed some areas where 
there might be room for improvement in asthma care. The use of LABA as monotherapy is 
strongly discouraged, yet a large proportion seemed to use them as monotherapy. However, 
this situation may have improved in later years as drug regulators and other bodies have 
issued several warnings. The apparent use of SABA as monotherapy was high in the older age 
groups. This could be due to these individuals having mild, intermittent asthma where such 
treatment is warranted, or it could represent under-treatment with controller drugs. A more 
thorough analysis of this issue should focus on the intensity of such treatment. Furthermore, 
among those who receive controller drugs, intensive use of SABA could be an indicator of 
suboptimal asthma control. The quality of care in those who receive asthma therapy could be 
improved by e.g. education of the patients on benefits and harms of the different drugs.  
 
To assess outcomes of asthma therapy, there is a need for outcome data. The Norwegian 
Patient Registry (NPR) with nationwide hospital inpatient diagnostic data can provide 
information on asthma outcomes and may be linked to NorPD data in future studies. 
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Key points:  
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 A majority of the asthma population had one of the comorbidities measured and few had 
more than one. 
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ABSTRACT
Purpose: 
To examine occurrence of chronic diseases and antimicrobial treatment in an asthma 
population 8-29 years old, compared to the general population.  
 
Methods: 
In this cross-sectional study, the asthma population was identified from the general population 
(retrieved from a census covering the entire Norwegian population) by using filled 
prescriptions on asthma drugs as a proxy measure of current asthma. The outcome was excess 
occurrence of specific diseases (comorbidity) among asthmatics, compared to the age-specific 
general population. Diseases were defined by filled prescriptions with specific diagnostic 
codes (ICPC-2 or ICD-10) during a 1-year period in the Norwegian Prescription Database. 
Nine chronic diseases were examined: ADHD, epilepsy, migraine, mental illness, 
cardiovascular disease, diabetes, autoimmune disorders, GORD, allergy. Additionally, 
antibacterials recommended for respiratory tract infections and antivirals were examined 
(defined by ATC codes). Standardized Morbidity Ratios (SMR) for each disease was 
calculated. 
 
Results: 
59% of the asthmatics had at least one of nine chronic diseases examined, compared to 18% 
in the general population. Few asthmatics had more than one additional chronic disease (6% 
of males, 8% of females). SMRs were increased for all diseases except diabetes, implying 
higher than expected occurrence of the specific diseases in asthmatics. This pattern was 
observed in both age groups (8-19 and 20-29 years) and genders. Allergy and GORD had 
highest SMR (range 3.2-4.8) while the other diseases were in the range 1.2-2.5. 
 
Conclusions: 
An excess occurrence of comorbidities was found in asthmatics. A majority of asthmatics had 
one additional chronic disease, and few had more than one. 
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INTRODUCTION
There is increasing recognition that co-occurrence of multiple chronic diseases is common 
also in children and has a significant impact on the overall health of patients.1-3 The extent and 
impact of comorbidities in asthmatics has received little attention compared to other chronic 
diseases like cardiovascular diseases and diabetes, possibly because multimorbidity increases 
with age1 while asthma is most prevalent in young populations.  
 
From the societal point of view, health service use is higher in asthmatics with comorbidities 
and places an extra burden on the healthcare system.4,5 At the patient level, comorbidities 
influence several aspects of asthma, such as detection and diagnosis, severity and control of 
asthma symptoms.6-8 Identification and treatment of comorbidities is part of the core 
management of asthma, especially for more severe cases.9 Associations between asthma and 
allergy, gastro-oesophageal reflux disease (GORD) and infections are well-established9-12 
while several other diseases have also been associated with asthma in population-based 
studies.7,13-15 However, few studies include children and adolescents.  
 
There is currently no systematic recording of diagnostic information in the Norwegian home-
dwelling population. Thus, opportunities to study the occurrence of diseases in the population 
have been limited. However, a change in the reimbursement system for drugs may enable us 
to assess occurrence of diseases in the whole population. From March 2009, it became 
mandatory to provide the diagnostic code (ICPC-2 or ICD-10) of the treated medical 
condition on all reimbursed prescriptions. The Norwegian Prescription Database (NorPD)16 is 
one of the first nationwide prescription databases to record this information. These codes may 
serve as surrogate measures of the diseases present among individuals in ambulatory care. 
The diseases studied in the present paper have been associated with asthma in previous 
population-based studies7,13-15, are expected to be of some magnitude in this young 
population, drug treatment is central to the management of the disease, and drugs are 
reimbursable. 
 
The aim of the present study was to examine the occurrence of specific types of chronic 
diseases and antimicrobial treatment in an actively treated asthma population of children, 
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adolescents and young adults, compared to the occurrence in the Norwegian general 
population of the same age.  
MATERIALS AND METHODS 
Data sources and study design 
We conducted a cross-sectional study utilizing data from three datasets covering the entire 
Norwegian population. The datasets were linked by using the unique, encrypted 11-digit 
person identity number (PIN), assigned to all individuals residing in Norway.16 
 
The latest Population and Housing Census (PHC) included all persons resident in Norway on 
3rd November 2001 according to the Central Population Register (CPR).17 The PHC provided 
a closed cohort of all Norwegians residents and variables used were the PIN, gender and birth 
year.  
 
The Central Population Register (CPR) contains continuously updated data on every person 
residing in Norway.18 The CPR provided information on date of death and emigration 
between the PHC in 2001 and the end of the study period. 
 
The Norwegian Prescription Database (NorPD) stores electronic data on all filled 
prescriptions from Norwegian pharmacies since January 2004. Pharmacies are obliged to send 
the data, irrespective of reimbursement status of the dispensed drugs and the prescribers’ 
specialty and occupation.16 Thus, NorPD has complete coverage of drugs dispensed to the 
home-dwelling population. Variables from NorPD used in the present study were the PIN, 
date of dispensing drug, reimbursement code (diagnostic code from March 2009) and the 
Anatomical Therapeutic Chemical (ATC)19 classification code of drugs.  
Measure of comorbidities 
Diagnostic codes from reimbursed drug prescriptions registered in NorPD were used to define 
the outcome (comorbidities). 
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Reimbursement scheme with diagnostic codes: Reimbursement of drug costs is a part of the 
national, tax-supported public health service which all Norwegians have unrestricted access 
to.20 The drug reimbursement scheme is based on a list of conditions for which specified 
drugs can be reimbursed. Reimbursement should only be granted if the patient has a chronic 
condition where long term treatment is needed (at least 3 months of regular or intermittent 
treatment during a year). From March 2009, physicians were obliged to provide the diagnostic 
code of the condition being treated on prescriptions deemed eligible for reimbursement. 
Codes from either the International Classification of Diseases version 10 (ICD-10) or the 
International Classification of Primary Care version 2 (ICPC-2) can be used. The Norwegian 
Medicines Agency (NoMA) has defined about 20 additional codes for conditions that have no 
appropriate ICD-10 and/or ICPC-2 code, some of which has been included in our study (see 
comments in Table 1).  
 
Occurrence of a comorbid disease: The presence of a comorbid chronic disease in an 
individual was defined as filling at least one reimbursed prescription with a diagnostic code 
during a 1-year period. These diagnostic codes were used as surrogate measure of disease. 
The following nine chronic diseases were examined: Attention Deficit Hyperactivity Disorder 
(ADHD, denoted “hyperkinetic disorder” in ICD-10 and ICPC-2), epilepsy, migraine, mental 
illness, cardiovascular disease, diabetes (type 1 and 2), autoimmune disorders, gastro-
oesophageal reflux disease (GORD) and allergy (Table 1).  
To study occurrence of antimicrobial treatment (normally not reimbursed), ATC codes 
on drugs dispensed were used instead of diagnostic codes (Table 1). Antibacterials 
recommended in Norwegian guidelines21 for use in upper and lower respiratory tract 
infections were included, as well as antivirals used for influenza virus infections. 
Comorbidity may be defined as the occurrence of one or more additional diseases in 
individuals who have an index disease.22 For brevity, the term “comorbidity” will be used in 
the present paper for the occurrence of any of the diseases also in the general population who 
do not necessarily have the index disease (asthma). 
 
Index date and study period: From 3 March 2009, physicians were obliged to write diagnostic 
codes on all reimbursed prescriptions, and this date was therefore set as the index date. NorPD 
data on the outcome (comorbidity) for a 1-year period after the index date was retrieved for 
the Norwegian general population and for the study population of asthmatics.  
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Standard population: Norwegian general population 
The standard population included all persons who participated in the PHC in 2001 and were 
under 30 years in 2009 (653,386 males, 620,453 females). Individuals who according to CPR 
data died or emigrated before the end of the study period (2 March 2010) were excluded 
(16,282 males, 18,024 females). Thus, 637,104 male and 602,429 female residents in Norway 
aged 8-29 years in 2009 comprised the standard population. Because the PHC was conducted 
in 2001, the lowest age class that could be studied was 8 years old. 
Study population: Current asthmatics in the general population 
The study population was all current asthmatics receiving drug treatment that could be 
identified in the standard population (20,207 males, 16,853 females). A proxy measure based 
on dispensed asthma drugs was used to identify this population, a measure described in 
previous NorPD studies.23,24 Included were those who had filled prescription for an asthma 
drug at least once in the year before and at least once in the year after the index date. Only 
prescriptions with reimbursement codes for asthma were included. Asthma drugs were 
defined as inhaled 2-agonists (ATC code R03AC), inhaled glucocorticoids (R03BA), 
combination inhalers with 2-agonists and glucocorticoids (R03AK), and leukotriene receptor 
antagonists (R03DC).  
Statistical methods 
The number of comorbidities occurring in the asthma population and in the general population 
was examined as the proportion of the populations having respectively 0, 1, 2, 3, and 4 or 
more comorbidities (Table 2). 
 
Associations of asthma with specific comorbidities were examined by calculating 
Standardized Morbidity Ratios (SMR) (Table 3). The occurrence of each disease (prevalence 
proportion) was calculated for 1-year age-specific groups in the general population and 
separately for males and females. From these prevalence proportions, Expected counts (E) in 
the asthma population were calculated, while Observed counts (O) were retrieved in the same 
manner as for the general population. The O/E ratio (SMR) was calculated with 95% 
confidence intervals from the Poisson distribution. Results were stratified by gender and age 
(8-19 years and 20-29 years). Note that the magnitude of the SMRs is not directly comparable 
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between the different genders and age groups, because they are compared to different 
standard populations.  
 
The study was approved by the Norwegian Data Inspectorate, and the Regional Committee 
for Medical Research Ethics evaluated it. 
RESULTS
Occurrence of nine chronic comorbidities was studied. 59% of male and female asthmatics 
had at least one of the comorbidities, compared to 18% of males and females in the general 
population (Table 2). Relatively few in the asthma population had more than one of these 
comorbidities (6% of males, 8% of females). When antimicrobial treatment was included, 
69% of male and 71% of female asthmatics had at least one comorbidity, compared to 30% 
and 34% in the general population. 
 
The occurrence of specific comorbidities in the asthma population is presented in Table 3. 
The prevalence proportion (O/n) of asthmatics having allergy was above 50% for all groups, 
while antibacterial treatment was also relatively prevalent in asthmatics (13-31%). The 
prevalence was higher in the oldest age group for all comorbidities except allergy in males, 
ADHD and antivirals. The largest percentage point difference in prevalence between the low 
and high age group were observed for migraine in females and for mental illness, as well as 
for the highly prevalent diseases (allergy, antimicrobials). 
 
The SMR estimates generally showed an increased occurrence for all diseases, except 
diabetes (Table 3). This pattern was consistent in all gender and age groups and implies a 
higher than expected occurrence of the specific diseases in the asthma population compared to 
the gender- and age-specific general population. GORD and allergy had high SMRs (range 
3.2-4.8). The other diseases were in the range 1.3-2.1, except for diabetes and ADHD which 
showed inconsistent patterns.  
 
Diabetes was the only disease that did not have a consistent increased SMR for asthmatics, 
and was even below 1.0 for the youngest females. In an additional analysis, we only included 
the diagnostic codes that are more specific for diabetes type 1 (ICPC “T89 Insulin-dependent 
 8 
  
diabetes mellitus”, and ICD “E10 Diabetes mellitus type I”). This gave SMR of 1.3 [1.0-1.6] 
for youngest males and 1.1 [0.8-1.5] for the oldest males. For females, the numbers were 
respectively 0.8 [0.5-1.1] and 0.9 [0.6-1.3].  
DISCUSSION 
In this study of children, adolescents and young adults, we found that chronic diseases were 
present more often in asthmatics than in the general population. Likewise, use of specific 
antimicrobial treatments occurred more frequently among asthmatics. The present study is the 
first to examine asthma and comorbid diseases in the entire Norwegian population by using 
the diagnostic codes from NorPD. Our results obtained from diagnostic codes on prescriptions 
are essentially in line with studies that obtained diagnostic information from administrative 
data or self-reports. 7,13-15 However, most studies are in adults and few have reported age-
stratified results. 
 
Adams et al.14 found associations of asthma and diabetes but not arthritis in adults 18-34 years 
old, but an association was present in older age groups. Cazzola et al.13 reported hypertension, 
allergic rhinitis, diabetes, dyslipidemia, depression and GORD to be associated with asthma. 
Associations were generally weaker in 15-34 year olds compared to older adults except for 
allergic rhinitis, depression and diabetes. Prosser et al.15 found asthma to be associated with a 
wide range of diseases in adults, including infections in the lower and upper respiratory tract, 
depression, hypertension, diabetes and certain autoimmune disorders. Zhang et al.7 found 
associations with allergy, arthritis/rheumatism, hypertension, diabetes and mental illness in an 
adult population. Most chronic conditions were more prevalent in adults but allergies and 
mental illness were more frequent in 18-34 year olds.  
 
In studies of specific diseases, anxiety and depression has been associated with asthma25-27 
and a bidirectional relationship has been suggested.25 The association may be dependent on 
how asthma is defined.28,29 Asthma has been found to be associated with migraine in 
adults.30,31 In studies comparing epileptics to non-epileptics, an association with asthma has 
been reported.32,33 ADHD and asthma are most prevalent in children and adolescents, and this 
is reflected in our data by ADHD being one of the more prevalent comorbidities of asthma. 
Associations with ADHD have been reported in the literature, including a NorPD study that 
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used ATC codes as proxy measures for diagnosis of both diseases.34,35 Associations between 
diabetes and asthma has been found in several studies in adults. 7,13-15 Our data had a 
relatively few diabetes cases among asthmatics and did not show a consistent association. Of 
note is that a high proportion of participants in our young study population are expected to be 
type 1 diabetics, while studies among adults will be predominated by type 2 diabetics. For 
GORD, the absolute numbers (prevalence) is lower in asthmatics in our study than reported in 
the literature among children11 and adults12, possibly because it has not been diagnosed and 
subsequently treated with prescription drugs (over-the-counter drugs are also available). 
However, the strong relative association (SMR) is reported in other studies as well.11,12 Links 
between asthma and allergies and respiratory infections are well known and receive much 
attention in asthma guidelines.9,10 An association between asthma and antibacterials is 
difficult to disentangle from associations of asthma and infections themselves, and the present 
study was not designed for this purpose. 
 
Our measure of comorbidity will capture chronic diseases diagnosed by a physician, where 
the physician and the patient have chosen to treat with drugs in the ambulatory setting. The 
study is cross-sectional and the temporal sequence events can not be determined. The 
associations observed may have several explanations and we will discuss three possibilities.  
 
First, there may be a genuinely increased co-occurrence of other diseases in asthmatics. This 
may be due to a pathway where one problem is central to development of the other. For 
example, the comorbidity may be a risk factor for development of asthma, or for triggering 
asthma symptoms and increasing severity. The causal link may be reversed, in that asthma 
contributes to development of other diseases. Alternatively, asthma and comorbidities may be 
indirectly linked via common genetic and environmental factors for development of disease.  
 
Second, there may be a higher detection rate of comorbidities in asthmatics, i.e. detection bias 
occurs.36 This may be an issue in any epidemiologic study where health care service use is 
measured. Asthmatics do more often than their healthy peers visit physicians for monitoring 
of the disease and prescription renewals. Any additional health problems more easily come to 
the attention of physicians and a prescription for a drug may ensue. This may also go the 
opposite direction in that asthma is more easily detected in individuals who have other 
reasons for visiting a physician. This kind of bias is probably most pertinent in milder, 
intermittent cases of asthma, and for comorbidities with a high proportion of subclinical cases 
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that are not usually detected. An increased detection rate of diabetes and epilepsy seems less 
likely due to the severity of these diseases. Furthermore, our definition of the asthma 
population will have excluded some milder cases of asthma and individuals who tried asthma 
drugs only once as part of diagnosing respiratory complaints. 
 
Third, some individuals may have a lower threshold for seeking healthcare services including 
drug treatment, and/or some physicians have a lower threshold for setting a diagnosis and 
prescribing drugs. Use of healthcare services may be a learned behavior where asthmatics 
who often are in contact with their physician will likely be more aware of their illnesses and 
may have learned to use, and possibly overuse, healthcare services. In support of the latter 
explanation are studies reporting a higher occurrence of a broad range of different conditions 
in asthmatics.5,7,13-15 It would be interesting to find a “reference disease” that is not linked to 
asthma and study if there is an excess occurrence of this “reference disease”.  
 
The asthma drugs used to identify our asthma population are the mainstay of asthma 
pharmacotherapy9 and are quite specifically used for asthma at this age. Largely all patients 
on anti-asthma treatment in Norway receive at least one of the included drugs23 and a high 
validity of this measure was found in 7-year olds.24 In the present study, we used a stricter 
criterion for defining the asthma population in that asthmatics had to fill at least two 
prescriptions and at least one year apart. Thus, the inception of asthma complaints took place 
before the 1-year study period and lasted for at least one year (persistently or episodes of 
asthma at least one year apart).  
 
A limitation of the study is the cross-sectional design which unable us to determine a causal 
relationship between comorbidities and the occurrence of asthma. The recording of diagnostic 
codes has only recently been implemented but when more years of data are accumulated, 
long-term studies can be done to confirm our findings and to disentangle sequence of events. 
The time period of one year may be too short to capture some comorbidities, e.g. individuals 
with infrequent episodes of migraine may have long gaps between prescription refills. The 
length of study period is especially pertinent when studying a time-varying disease such as 
asthma where disease activity, and the use of asthma drugs,23 is variable over shorter and 
longer time periods. A possible detection bias was discussed above. A further limitation is 
that for allergy and GORD, over-the-counter drugs without reimbursement are available. 
Some individuals may also have used non-reimbursed prescription drugs. This is probably 
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most relevant for migraine and mental illnesses, if the physician deems the disease as not 
chronic or not properly diagnosed yet. Patients have economic incentives for receiving their 
drugs on reimbursement but acquiring a prescription may be more convenient for asthmatics 
due to higher physician visit frequency.  
 
One of the strengths of our study is that we use individual level data from three complete, 
nationwide datasets. NorPD captures all individuals receiving prescription drugs in the 
ambulatory care setting, including drugs prescribed by specialists in secondary and tertiary 
care. The universal healthcare system should ensure access to necessary healthcare services 
for all residents. Thus, we could examine the occurrence of a broad range of diseases in the 
Norwegian general population of the entire age range. The method for identifying chronic 
diseases is consistent between diseases and does not rest on subjective judgment by patients 
about their disease as in self-report studies, while recall bias is eliminated. However, the 
choice by patients and physicians to use drugs for a medical condition may be influenced by 
subjective judgments, as discussed above. 
 
Comorbidities may influence and complicate several aspects of asthma, such as detection and 
diagnosis, severity and control of asthma symptoms.6-8 Furthermore, the response to asthma 
therapy may be altered (e.g. obesity alter response to corticosteroids37) or adherence to asthma 
therapy decreases (e.g. depression28,38). The drugs used for the treatment of comorbid diseases 
can have detrimental effects on asthma (e.g. NSAIDs9). 
 
In summary, by using a nationwide prescription database with diagnostic codes we have 
shown an excess occurrence of several chronic diseases in the young population of 
asthmatics, compared to the age-specific general population of Norway. 59% of the asthma 
population had at least one additional chronic disease, while relatively few had more than one 
additional disease. 
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Table 1: Comorbidities and corresponding diagnostic codes (ICPC-2 and ICD-10 codes) 
examined in the Norwegian Prescription Database (NorPD). 
 
Comorbidity ICPC-2 ICD-10 Comment
Attention Deficit Hyperactivity 
Disorder (ADHD)a
P81 F90 a) Denoted as hyperkinetic disorder in 
ICPC and ICD coding systems.
Epilepsy N88 G40
Migraine N89 G43
Mental illness
  -depression
  -anxiety
-74b; P74; 
P76
-74b; F41; 
F32
b) Reimbursement code for anxiety 
disorders, defined by NoMA (replaces 
ICPC and ICD codes).
Cardiovascular disease
-hypercholesterolaemia
  -hypertension
-26c; -27c; 
K86-87
-26c; -27c; 
I10-13; I15
c) Reimbursement codes for primary and 
secondary prevention of atherosclerotic 
disease, defined by NoMA (replaces 
ICPC and ICD codes).
Diabetesd
  -type 1
  -type 2
T89-90 E10-11; 
E13-14
d) ICPC codes do not distinguish 
between diabetes type 1 and 2.
Autoimmune disorders
  -arthritis related diseases
  -systemic connective tissue disorders
  -ankylosing spondylitis
  -noninfective enteritis and colitis
  -psoriasis
L88; L99; 
D94; S91
M05-08; M13; 
M30-35; M45; 
K50-51; L40
Gastro-Oesophageal Reflux 
Disease (GORD)e
D84 K21 e) OTC drugs also on market but are not 
reimbursed.
Allergyf
  -allergic rhinitis
  -allergic conjunctivitis
  -atopic dermatitis
  -urticaria
R97; F71; 
S87; S98
J30; 
H10.1g;
L20; L50
f) OTC drugs also on market but are not 
reimbursed.
g) NoMA specifies that only the 4th level 
code H10.1 is eligible for reimbursement.
Antibacterialsh
  -upper and lower respiratory tract
   infections
h) Drugs (ATC codes) recommended by 
guidelines† for treatment of upper and 
lower respiratory tract infections.
Antiviralsi
  -influenza virus infection
i) H1N1 influenza during study period. 
Pharmacists could write prescriptions 
and dipsense drugs according to set 
regulations, without consulting 
physicians.
† Norwegian Directorate of Health. [Norwegian national guidelines for treatment with antibiotics in general practice]. 2008. Available from: 
   http://www.helsebiblioteket.no/microsite/Antibiotikaretningslinjer (in Norwegian).
C
hr
on
ic
 d
is
ea
se
s
ATC codes: 
J05AH01; J05AH02 
Abbreviations:  NoMA, Norwegian Medicines Agency; OTC, Over-the-counter-drugs (drugs sold without precription); ATC, Anatomical 
Therapeutic Chemical classification system for drugs; ICPC-2, International Classification of Primary Care, 2nd edition; ICD-10, International 
Statistical Classification of Diseases, 10th revision.
ATC codes: 
J01AA02; J01CA04; 
J01CE02; J01FA
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Table 2: Number of comorbid diseases occurring in the asthma population and the general 
population (8-29 years old) during a 1-year period. 
 
% of asthma 
populationa
% of general 
population
% of asthma 
populationa
% of general 
population
(n=20,207) (n=637,104) (n=16,853) (n=602,429)
Chronic diseasesb
0 40.8 82.4 41.4 81.9
1 53.3 16.2 50.4 16.2
2 5.3 1.3 6.9 1.6
3 0.6 0.1 1.0 0.2
4+ 0.1 0.0 0.2 0.0
0 30.7 70.2 29.1 66.4
1 48.2 24.3 44.6 26.3
2 17.3 4.8 20.0 6.1
3 3.3 0.6 5.2 1.0
4+ 0.5 0.1 1.1 0.2
a) Not adjusted to the age-distribution of the general poulation.
c) 11 different comorbidities measured, see Table 1.
b) 9 different comorbidities measured, see Table 1.
Males Females
Chronic diseases and 
antimicrobial treatmentc
Number of 
comorbidities
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Table 3: Standardized Morbidity Ratio (SMR) for occurrence of comorbid diseases in the 
asthma population (8-29 years old) during a 1-year period (Reference: Occurrence of diseases 
in the general population by gender and 1-year age specific groups). 
 
Occurrence 
(O/n)
Observed 
count (O)
Expected 
count (E)
SMR 
(O/E)
Occurrence 
(O/n)
Observed 
count (O)
Expected 
count (E)
SMR 
(O/E)
ADHD 4.0 % 585 469 1.2 [1.1 , 1.4] 2.2 % 223 129 1.7 [1.5 , 2.0]
Epilepsy 1.0 % 149 84 1.8 [1.5 , 2.1] 1.1 % 111 56 2.0 [1.6 , 2.4]
Migraine 0.9 % 133 76 1.7 [1.5 , 2.1] 2.0 % 203 118 1.7 [1.5 , 2.0]
Mental illness 0.4 % 65 39 1.7 [1.3 , 2.1] 0.9 % 90 67 1.3 [1.1 , 1.7]
Cardiovascular 0.1 % 20 13 1.5 [1.0 , 2.3] 0.2 % 21 12 1.8 [1.1 , 2.7]
Diabetes 0.6 % 83 62 1.3 [1.1 , 1.7] 0.4 % 37 43 0.9 [0.6 , 1.2]
Autoimmune 0.7 % 103 66 1.6 [1.3 , 1.9] 1.0 % 104 67 1.5 [1.3 , 1.9]
GORD 1.6 % 236 52 4.6 [4.0 , 5.2] 1.3 % 134 34 4.0 [3.3 , 4.7]
Allergy 56.1 % 8258 1 977 4.2 [4.1 , 4.3] 51.8 % 5274 1 098 4.8 [4.7 , 4.9]
Antibacterialsd 13.8 % 2024 1 212 1.7 [1.6 , 1.7] 19.6 % 1994 1 212 1.6 [1.6 , 1.7]
Antiviralsd,e 13.8 % 2033 986 2.1 [2.0 , 2.2] 13.1 % 1330 684 1.9 [1.8 , 2.1]
ADHD 1.6 % 89 39 2.3 [1.8 , 2.8] 1.6 % 108 42 2.5 [2.1 , 3.1]
Epilepsy 1.3 % 69 39 1.8 [1.4 , 2.2] 1.4 % 93 49 1.9 [1.6 , 2.3]
Migraine 1.1 % 60 37 1.6 [1.3 , 2.1] 5.6 % 370 198 1.9 [1.7 , 2.1]
Mental illness 4.5 % 249 134 1.9 [1.6 , 2.1] 7.7 % 510 266 1.9 [1.8 , 2.1]
Cardiovascular 1.3 % 69 39 1.8 [1.4 , 2.2] 1.2 % 77 40 1.9 [1.5 , 2.4]
Diabetes 0.8 % 45 41 1.1 [0.8 , 1.5] 1.0 % 64 46 1.4 [1.1 , 1.8]
Autoimmune 1.9 % 104 80 1.3 [1.1 , 1.6] 2.8 % 188 121 1.5 [1.3 , 1.8]
GORD 3.3 % 179 56 3.2 [2.8 , 3.7] 2.7 % 183 52 3.5 [3.0 , 4.0]
Allergy 51.5 % 2831 591 4.8 [4.6 , 5.0] 55.9 % 3729 903 4.1 [4.0 , 4.3]
Antibacterialsd 22.9 % 1259 777 1.6 [1.5 , 1.7] 31.7 % 2113 1 370 1.5 [1.5 , 1.6]
Antiviralsd,e 9.7 % 534 251 2.1 [2.0 , 2.3] 11.1 % 739 389 1.9 [1.8 , 2.0]
c) Indviduals that have more than one comorbidity is counted on each comorbidity (sum of observed counts (O) on all comorbidities does not equate to the 
study population size).
d) From ATC codes on drugs.
e) H1N1 influenza epidemic during the observed 1-year period.
[95% CI]
Abbreviations:  ADHD, Attention Deficit Hyperactivity Disorder (hyperkinetic disorder); GORD, Gastro-Oesophageal Reflux Disease.
a) Males n=20,207 (8-19 years n=14,709; 20-29 years n=5.498).
b) Females n=16,853 (8-19 years n=10,187; 20-29 years n=6,666).
[95% CI]
Malesa
8-19 years 
20-29 years
Femalesb
Comorbidityc
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Appendix I 
Pilot questionnaire for 7-year old children in the 
Norwegian Mother and Child Cohort Study (MoBa)  
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Forts. neste side
1. Har barnet eller har det noen gang hatt noen av følgende langvarige sykdommer eller helseproblemer? 
  Hvis ja, hvor Hvis barnet er    
  gammelt var barnet  kvitt sykdommen, Ja, har Sett kryss hvis
  ved første tegn ved hvilken alder sykdommen sykdommen er
 Ja på sykdommen. skjedde det? fremdeles. diagnostisert av lege 
  1 Astma           år           år   
  2 Allergi i øyne eller nese/høysnue           år           år    
  3 Atopisk eksem/barneeksem           år           år  
  4 Nedsatt hørsel           år           år  
  5 Nedsatt syn           år           år    
  6 Overvekt           år           år  
  7 For liten vektøkning           år           år   
  8 Søvnproblemer           år           år  
  9 Reumatoid artritt/leddgikt           år           år  
10 Hjertefeil           år           år    
11 Crohns sykdom           år           år  
12 Ulcerøs collitt           år           år  
13 Kronisk utmattelsessyndrom (ME)           år           år  
14 Cøliaki           år           år  
15 Diabetes           år           år  
16 Epilepsi           år           år  
17 Cerebral parese           år           år  
18 Anemi (lav blodprosent)           år           år  
Oppgi dag, måned og år for utfylling av skjemaet (skriv årstall med 4 tall, f.eks. 2008)
dag         måned                 år
Skjemaet skal leses av en maskin. Det er derfor viktig at du legger vekt på følgende ved utfyllingen:
• I de små avkrysningsboksene setter du et kryss for det svaret som du mener passer best, slik: 
• Hvis du mener at du har satt kryss i feil boks, kan du rette det ved å fylle boksen helt, slik: 
Spørreskjema 7, når barnet er ca 7 år
Sykdom og helseplager
x
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19 Kreft      år            år  
20 Forsinket motorisk utvikling      år            år   
21 Forsinket eller avvikende språkutvikling      år            år   
22 Hyperaktivitet/ADHD      år            år  
23 Autistiske trekk/autisme      år            år   
24 Asperger syndrom      år            år  
25 Atferdsproblemer (vanskelig og uregjerlig)      år            år  
26 Emosjonelle vansker/ (trist og engstelig)      år            år  
27 Allergi/intoleranse mot melk      år            år  
28 Allergi/intoleranse mot egg      år            år  
29 Allergi/intoleranse mot ﬁ sk      år            år  
30 Allergi/intoleranse mot andre matvarer      år            år  
Hvis ja, hvilke? 
Rug    Citrus frukter    Hvete    Soya    Skalldyr   Peanøtter    Nøtter (andre enn peanøtter)    Annet
2. Har barnet brukt medisin, spray, inhalator eller andre medikamenter for astma i løpet av det siste året?
  Nei
  Ja
3. Hvis ja, navn på medisin barnet bruker fast………………………………………………………………………………………………………………
4. Hvis ja, navn på medisin barnet bruker ved anfall……………………………………………………………………………………………………….
5. Hvis ja, når brukte barnet astmamedisiner sist?
 I går      Siste 7 dager      Siste måned      Siste året 
      
6. Har barnet noen gang hatt noen av følgende symptomer eller helseplager? Hvis ja, kryss av for i hvilken alder.
    Angi også hvor mange ganger barnet har vært plaget av dette de siste 12 måneder.
    
Hatt symptomer     Hvis ja, ved hvilken alder  
Ja.            Før 3 år   3-5 år   6-7år   Antall ganger  siste 12 mnd?
 
  1 Piping/hvesing i brystet                      
  2 Tetthet i brystet                      
  3 Nattlig hoste uten forkjølelse                      
  4 Tetthet/ piping i brystet under eller etter fysisk aktivitet                      
  5 Rennende nese uten forkjølelse                      
  6 Kløe/renning fra øyne uten forkjølelse                      
  7 Kløende utslett som har kommet og gått i minst 6 måneder                        
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10. Utenom skoletid på en vanlig hverdag: Hvor mange timer
per dag bruker barnet vanligvis på TV, video, elektroniske 
spill, DVD eller PC?
 Mindre enn 1 time 1-2 timer 3-4 timer 5 timer el mer               
Sommer     
Vinter      
12. Hvor ofte kommer barnet seg til skolen ved hjelp av  
 Aldri Av og til Vanligvis Alltid
Å gå/sykle      
Å bli kjørt     
Med kollektivtransport    
13. Hvor lang avstand er det mellom barnets bolig og skolen? 
 Mindre enn 1 km  1-2 km       3-4 km     Over 4 km
 8 Magesmerter                      
  9 Migrene                       
10 Annen hodepine                       
11 Oppkast/diaré                      
12 Feberkramper                       
13 Halsbetennelse                      
14 Ørebetennelse                      
 15 Bronkitt                      
16 Lungebetennelse                      
17 Urinveisinfeksjon                      
18 Bruddskader                      
19 Andre skader                       
20 Hjernehinnebetennelse/meningitt                   
21 Andre symptomer eller sykdommer                     
Beskriv hvilke………………………………………………………………………………………………………………………………………………………... 
8. Utenom skoletid: Omtrent hvor mange timer per uke driver
barnet fysisk aktivitet eller idrett (for eksempel sykling, turn,
hopping på trampoline, ski, fotball o.l)? 
 Mindre 1-2  3-4  5-7 8-10 11 timer
 enn 1 time timer timer timer timer eller mer
Sommer        
Vinter         
11. Har barnet badet i et innendørs svømmebasseng
i løpet av de siste 12 måneder? 
  Nei 
  Ja, av og til                 Antall timer per måned                 
  Ja, ukentlig                 Antall timer per uke                       
Levevaner og livsstil
7. Hvor mange dager har barnet vært borte fra skolen eller
hatt avbrudd i lek eller fritidsaktivitet på grunn av sykdom? 
Antall dager borte fra skolen siste 3 mnd.                  dager 
Antall dager avbrudd i lek/fritidsaktivitet siste 3 mnd.                      dager
9. Utenom skoletid på en vanlig hverdag: Hvor mange timer 
per dag er barnet vanligvis utendørs?
Sommer                          timer
Vinter                          timer
+
+
++
+
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27. Hva er barnets høyde og vekt? Oppgi dato for målingen og
kryss av for hvem som målte høyde og vekt.  
Høyde                                   m            Vekt                             kg     
Dato for måling
Målt selv      Målt av lege/helsesøster  
,
Barnets kosthold
30. Hvor ofte børstes barnets tenner (av barnet selv eller andre)?
 To ganger per dag eller oftere  Av og til
 En gang per dag  Aldri
 
33. Bruker barnet ﬂ uortabletter?
  Nei   Ja
  Av og til
32. Har barnet fått fyllinger i noen av tennene sine? 
 Nei 
 Ja 
28. Hvor gammelt var barnet da hun/han ﬁ kk sin
første melketann?
Antall måneder       Husker ikke 
29. Hvor gammelt var barnet da hun/han felte sin
første melketann?
Antall år      Husker ikke  Har ikke felt ennå 
22. Brukte dere vedfyring i barnets hjem i perioden før 
barnet fylte 3 år?
  Nei
  Ja
23. Er det dyr i barnets hjem?
  Nei
  Ja
25. Er barnet i kontakt med gårdsdyr minst en gang i 
løpet av en uke?
  Nei
  Ja
24. Hvis ja, hvilke?
  Hund   Fugl 
  Katt   Annet      
  Andre pelsdyr (marsvin, kanin o.l)  
20, Hvis ja, bruker dere en vedovn laget før 1997?
  Nei
  Ja
21. I løpet av det siste året har dere noen gang brukt 
åpen peis? 
  Nei, aldri
  Ja, av og til
  Ja, ofte i vinterhalvåret  
  Ja, daglig i vinterhalvåret
26. Hvis ja, hvilke?
  Hest   Gris  Høner/fjærkre
  Sau/geit   Storfe  Annet  
18. I løpet av det siste året, har vedfyring blitt brukt til 
oppvarming i boligen der barnet bor?
  Nei
  Ja
19. Hvis ja, er vedfyring hovedkilden til oppvarming i 
denne boligen?
  Nei
  Ja
16. Hvis nei, Hvor mye er barnet sammen med henholdsvis
mor og far?    
 Mor Far
Mer enn halvparten av tiden    
Omtrent halvparten av tiden      
Mindre enn halvparten av tiden      
Sjelden      
Aldri    
34. Hvor mange skiver brød/knekkebrød spiser barnet ditt vanligvis per dag? 
           Loff                      Antall skiver        Lyst og mellomgrovt brød                      Antall skiver
Grovt brød                      Antall skiver                              Knekkebrød                      Antall skiver
15. Bor du sammen med barnets far?
   Nei
   Ja
14. Hvor mange timer sover barnet vanligvis i gjennomsnitt per 
natt på hverdager?
Antall timer                  
17. Hvordan er røykevanene i hjemmet nå for tiden?
 Deg selv  Din samboer/ektefelle 
Røyker ikke     
Røyker av og til                      
Røyker daglig                     
Hvis daglig, antall sigaretter per dag per dag
Hvis av og til, antall sigaretter per uke per uke   
31. Får barnet for tiden hjelp til å pusse tennene?
  Daglig   Sjelden eller aldri
  Flere ganger i uken
dag         måned                     år
+ +
+
+
+
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36. Hvor ofte drikker barnet ditt vanligvis følgende? (Sett ett kryss for hver drikke)
Drikke                              1-3 glass per mnd. 1-3 glass 4-6 glass     1-3 glass 4 glass
                                   Aldri eller sjeldnere per uke per uke  per dag eller mer per dag 
Helmelk (søt/sur)             
Lett-/ekstra lettmelk/Skummet melk            
Sjokolademelk                      
Biola/Culturamelk                      
Appelsinjuice, annen juice                      
Eplenektar / annen nektar                
Saft med sukker                      
Saft kunstig søtet                       
Brus (Cola o.l.)                       
Brus kunstig søtet (Pepsi max o.l)                       
Vann                       
37. Hvor ofte spiser barnet ditt vanligvis disse matvarene/rettene?  (Sett ett kryss for hver linje.)
Middagsmat                               1-3 ganger per mnd. 1-2 ganger 3-4 ganger     5-6 ganger 1 gang per dag   
                                   Aldri eller sjeldnere per uke per uke  per uke eller oftere   
Fet ﬁ sk (laks, makrell, sild)             
Annen ﬁ sk (torsk, sei o.l)                         
Fiskeboller/ﬁ skepudding o.l.          
Kylling/kalkun          
Rent kjøtt          
Pølser          
Kjøttdeig, (hamburger o.l.)          
Pizza          
Pannekaker          
Vegetarretter          
Poteter          
Ris, spagetti, pasta          
38. Hvor ofte spiser barnet ditt vanligvis følgende?  (Sett ett kryss for hver linje.)
Grønnsaker og frukt  1-3 ganger per mnd. 1-2 ganger 3-4 ganger     5-6 ganger 1 gang per dag     
                                   Aldri eller sjeldnere per uke per uke  per uke eller oftere   
Gulrot      
Kålrot      
Kål, blomkål, brokkoli      
Spinat, grønne bønner       
Erter      
Andre grønnsaker      
Appelsin, klementiner      
Banan      
Eple, pære      
Druer, melon      
Annen frisk frukt eller bær      
Økologisk dyrket frukt eller grønnsaker      
35. Hvor ofte spiser barnet ditt vanligvis følgende? Sett ett kryss for hver linje.
Pålegg og frokostblandinger                 1-3 ganger per mnd. 1-2 ganger 3-4 ganger     5-6 ganger 1 gang per dag                        
           Aldri eller sjeldnere per uke per uke  per uke eller oftere   
Ost (gul/brun), prim             
Kjøttpålegg (servelat, skinke ol)                         
Fiskepålegg, inkl kaviar                      
Egg                      
Syltetøy/honning                      
Sjokolade- og nøttepålegg                      
Corn Flakes, Honey Corn, Frosties o.l.                
Müsli/havregryn/frokostblanding                      
Yoghurt naturell                       
Fruktyoghurt/drikkeyoghurt                       
+
+
+
+
+
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41. Tar barnet ditt vanligvis følgende?  (Sett ett kryss for hver linje.)
Kosttilskudd Nei Ja, av og til Ja, daglig
Tran                  
Andre ﬁ skeoljer/omega-3                  
Multivitamintilskudd                  
Hvis ja, navn på multivitamintilskudd ……………………………………………………………………………………………………………………………
Annet kosttilskudd                 
Hvis ja, navn på annet kosttilskudd:   ……………………………………………………………………………………………………………………………
39. Hvor ofte spiser barnet ditt vanligvis følgende?  (Sett ett kryss for hver linje.)
Godteri og snacks                              1-3 ganger per mnd. 1-2 ganger 3-4 ganger     5-6 ganger 1 gang per dag
                                   Aldri eller sjeldnere per uke per uke  per uke eller oftere 
Boller/vaﬂ er/kaker             
Is og melkedesserter                         
Sjokolade, sukkertøy/smågodt                      
Peanøtter                      
Potetchips o.l.                       
40. Hvor ofte spiser barnet ditt vanligvis følgende måltider sammen med familien? (Sett ett kryss for hver linje.)
  1-3 ganger per mnd. 1-2 ganger 3-4 ganger 5-6 ganger
 Aldri eller sjeldnere per uke per uke per uke Daglig
Frokost      
Middag      
Kveldsmat      
Har du husket å fylle ut dato for utfylling av skjema på side 1?
Tusen takk for at dere fortsatt vil være med i Den norske mor og barn undersøkelsen!
Kommentarer
+
+
+
+
+
6
02/01/08
 
  
 
 
 
 
 
 
 
 
 
Appendix II 
Questionnaire from the Youth Health Surveys (YHS)  





  
 
 
 
 
 
 
 
 
 
Appendix III 

 Not asthmaAsthma in past, not nowCurrent and 
physician-
diagnosed 
asthma
Current but not 
physician-
diagnosed 
asthma
Yes
n=248 No
n=1808
Yes
n=133
No
n=115
Yes
n=122
No
n=11
Yes
n=96
No
n=19
Yes
n=3
No
n=1805
Ever asthma
Physician-diagnosis
Current asthma
Physician-diagnosisPhysician-diagnosis
Respondents
n=2,056
Asthma groups constructed from answers on the Norwegian Mother and Child cohort 
study (MoBa) pilot questionnaire for 7-year old children. 
 

  
 
 
 
 
 
 
 
 
 
Appendix IV 

Annual prevalence of filling at least 1 and at least 2* prescriptions (rx) for asthma drugs 
in 2007. Norwegian Prescription Database (NorPD). 
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Male 1+rx Males 2+rx Female 1+rx Females 2+rx*2+rx: Prescriptions had to be filled on different days.
 
  
 

  
 
 
 
 
 
 
 
 
 
Appendix V 

Anatomical Therapeutic Chemical (ATC) classification codes of drugs for obstructive 
airway diseases (R03), including asthma drugs. 4th level ATC codes. 
 
 
ATC code Name
R RESPIRATORY SYSTEM
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03A ADRENERGICS, INHALANTS
R03AA Alpha- and beta-adrenoreceptor agonists
R03AB* Non-selective beta-adrenoreceptor agonists
R03AC Selective beta-2-adrenoreceptor agonists
R03AH* Combinations of adrenergics
R03AK Adrenergics and other drugs for obstructive airway diseases
R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03BA Glucocorticoids
R03BB Anticholinergics
R03BC Antiallergic agents, excl. corticosteroids
R03BX* Other drugs for obstructive airway diseases, inhalants
R03C ADRENERGICS FOR SYSTEMIC USE
R03CA Alpha- and beta-adrenoreceptor agonists
R03CB* Non-selective beta-adrenoreceptor agonists
R03CC Selective beta-2-adrenoreceptor agonists
R03CK* Adrenergics and other drugs for obstructive airway diseases
R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03DA Xanthines
R03DB* Xanthines and adrenergics
R03DC Leukotriene receptor antagonists
R03DX Other systemic drugs for obstructive airway diseases
* No sale registered in Norway according to statistics from wholesalers (97) and 
  statistics from the Norwegian Prescription Database (87)  
 
 

